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The specter of Human Immunodeficiency Virus (HIV) or Acquired Immune Deficiency 
Syndrome (AIDS) has become increasingly prevalent since it first entered public 
awareness in 1982. The Center for Disease Control (CDC) estimates that approximately 1 
million people in the United States of America (USA) are living with HIV/ AIDS. More 
alarming is the fact that approximately 250,000 people remain unaware of their 
seropositivity status, therefore putting themselves and others at risk. Ignorance 
concerning HIV status is due largely to two factors: either failure to take an HIV test in 
the first place, or, a failure to retrieve results after testing. Despite the distinct possibility 
that anxiety plays a role in decisions concerning HIV testing an extensive literature 
review yielded no study that specifically examined the association between anxiety and 
HIV testing behavior. Thus, the purpose of the study was to determine the influence of 
anxiety, both general and specific, on prospective HIV testing behavior. The design of the 
study was correlational, examining how a group of independent variables (namely, 
various types of anxiety) impact two separate dependent variables (likelihood of being 
tested HIV and likelihood of returning for results of the HIV test results). Three hundred 
and forty seven participants were administered measures assessing anxiety, both at the 
broad or "global" level and at the narrower level of context-specific or domain-relevant 
anxiety. Each participant completed the State-Trait Anxiety Inventory (STAI), Self-Rated 
Anxiety Scale (SAS), Subscales of the Medical Anxiety Scale (MAS), Death Anxiety 
Scale (DAS), and the Multidimensional AIDS Anxiety Questionnaire (MAAQ). A 
stepwise multiple regression data analytic strategy was used to examine the data. 
Analyses suggested that AIDS-Specific Anxiety accounted for a significant amount of 
variance in the independent variable of the Likelihood of Receiving HIV Testing and that 
Hospital and X-Ray Anxiety, respectively, accounted for a significant amount of variance 
in the independent variable of Likelihood of Returning to Receive the Results of HIV 
Testing; however, variance attributed to each of the dependent variables that remained 
after stepwise regression, was low. Once the researchers controlled for extraneous 
variables such as the relevant demographic variables of gender, ethnicity, previous HIV 
testing history, past sexual history, and relationship status, the variables that had been 
retained in both the equations - AIDS-Specific Anxiety and Hospital and X-Ray Anxiety, 
respectively - no longer accounted for a significant amount of variance and none of the 
variables assessed in the study were retained in the models examining the influence of 
anxiety on Likelihood to Receive HIV Testing and Likelihood of Returning for HIV 
Testing Results. Although the current study did not yield the anticipated results, the 
findings contribute to research concerning the influence of personality variable on disease 
status. The findings presented here may present researchers with a starting point for 
further empirical endeavors. Considering the limitations of the study and applying the 
suggestions derived from frankly addressing those limitations, future research may 
indeed reveal a significant impact of anxiety on HIV testing behavior. 
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Review of Literature 
Acquired Immune Deficiency Syndrome (AIDS) has become, without a doubt, an 
international epidemic due to its worldwide prevalence. Even in light of evidence 
suggesting a "success in controlling the epidemic in some countries, and a decline in 
prevalence in others, AIDS is still the single most important health crisis the world faces" 
(Poku & Whiteside, 2006, p. 250). As Spearman (2006) notes, despite the exertion of 
considerable effort of the international medical community to develop a preventative 
vaccine, twenty years have passed and still no Human Immunodeficiency Virus (HIV) 
vaccine is available. 
Global Estimates (UNAIDS & World Health Organization [WHO], 2005) provide 
a numerical index of the magnitude of this problem. In 2005, 40.3 million individuals 
were estimated to be living with HIV/AIDS. Of these individuals approximately 38 
million of the infected individuals were adults (aged 15 to 49), and 2.3 million were 
children (aged under 15). In the United States of America (USA), the Center for Disease 
Control (CDC) estimated that at the end of 2003, between 1,039,000 to 1,185,000 
persons in the USA were living with this disease (CDC, 2004a). The CDC (2005) 
highlights several advances that have been made in an attempt to curb the growing 
number of people affected by the disease. Advances in fighting the disease include 
reductions in mother-to-child transmission; drug combinations that treat and delay the 
onset of AIDS; increased community level involvement in prevention efforts; better 
understanding of high risk communities as well as the implementation of several 
behavioral interventions. However, these successes are overshadowed by the fact that in 
the USA about 1 million people are living with HIV or AIDS. The more alarming number 
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is the approximately 250,000 people who are unaware of their infection, therefore putting 
themselves and others at risk. "Those who do not know that they are infected cannot take 
advantage of treatment and may unknowingly transmit HIV to others" (CDC, 2005, p. 
19). Among the prevention strategies suggested by the CDC is the promotion of early 
diagnosis of HIV, which entails nothing more than taking an HIV test to determine one's 
status. However, as noted above, many seropositive individuals remain unaware of their 
status. This ignorance concerning status is due to two factors, either these individuals 
have failed to take a test, or they have taken a test but failed to retrieve their results. 
A body of research has attempted to examine the reasons behind the failure to 
return for the results of HIV testing (Dinh, Detels, & Nguyen, 2005; Hightow et al., 2003; 
Strauss, Deren, Rindskopf & Falkin, 2002; Sullivan, Lansky & Drake, 2004) as well as 
the reasons that lead individuals either to seek out or avoid HIV testing (Lyter, Valdiserri, 
Kingsley, Amoroso & Rinaldo, 1987; Riess, Kim & Downing, 2001). It is purpose of the 
present study to evaluate the causes of testing avoidance, as well as the failure to return 
for HIV test results, by specifically examining the role of anxiety and various defense 
mechanisms in attitudes towards HIV testing and the results of HIV testing. 
HIV/AIDS 
The question arises as to why AIDS, as a public health threat and a disease, 
appears to be viewed as such a special case. Kiemle (1994) states that it is a result both of 
the heightened awareness that appears to accompany it and because it causes the loss of 
life and the investment of considerable money and resources. The author argues that the 
uniqueness of AIDS lies in several factors such as that it not only affects those who 
contract it on a biological level, but also on a profoundly emotional level as well; 
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moreover, the disease affects not only the sufferer, but also places a heavy load on the 
direct family of the sufferer, his or her significant others, as well as counselors, and 
society at large. Furthermore, the disease indiscriminately affects both young and old 
alike. The subject of AIDS combines many taboos such as sex and sexuality, disease, 
disability, death and dying; and AIDS holds a special status because it often elicits the 
overt stigmatizing of, and discrimination against, those with the disease. Moreover, AIDS 
provokes more anxiety and notice because it is incurable and prospects for a vaccine to 
combat it remain bleak (Kiemle, 1994). Although current research is ambiguous with 
regards to the exact origin and even the first reports of the disease, the following history 
is most often suggested. Prior to July 1982, AIDS consisted of nothing more than a few 
cases of a medically bizarre and an as-yet-unnamed complex of often rare diseases found 
in homosexuals and hunters in Western-Central Africa. The status of the disease changed 
irrevocably in 1982 when the term AIDS was coined and a 20-month-old child died from 
an AIDS-related infection contracted through a blood transfusion, at last providing a clear 
sign that the transmission of AIDS was not limited exclusively to homosexual contact. 
During the twenty-five years that have intervened between its discovery and the present 
date, scientific research has determined the virus that causes AIDS is HIV (Hutchinson, 
2001; Mayer, 2005; Moore, 2004; Morrow, Isenberg, Sobol, Strieker, & Kieber-Emmons, 
1991; Watts, Okello, & Watts, 1990) 
While a discussion of the mechanism of the disease is beyond the scope of the 
present study, AIDS, in brief, is a disease in which HIV significantly compromises the 
body's immune system. In order to understand HIV/AIDS it is important first to 
understand the working of the human immune system. In a healthy individual the 
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immune systems helps to identify and eliminate antigens: foreign materials or substances 
such as bacteria, viruses, and parasites. Additionally, the immune system also targets the 
individual's own cells that have become damaged in some way. The foundation of the 
immune system lies in specific types of cells that are at work, with white blood cells or 
leukocytes being the most prominent. Macrophages, a type of leukocyte are the body's 
first line of defense, surrounding the identified antigens and destroying them. 
Macrophages also serve another important purpose, signaling lymphocytes, which consist 
of two main groups, B and T cells. B cells function within the humoral branch of the 
immune system, releasing molecules that find and neutralize antigens. Immunoglobulin is 
produced and functions as an antibody and when it interacts with the antigen neutralizes 
it. When the task is completed, it creates memory B cells that remember the antigen; thus, 
the next time the antigen is introduced into the body, the immune system will respond 
much faster. T cells operate in the cellular branch of the immune system and instead of 
creating antibodies like B cells; a subgroup of T cells called killer T cells directly 
destroys the antigens. Another subgroup of T cells, called helper T cells, signals B cells 
to produce antibodies as well as signaling other T cells to destroy antigens. Yet another 
subgroup of T cells is called suppressor T cells; these function to suppress the production 
of antibodies by B cells when they are no longer needed. A very unique interaction 
between the humoral and cellular branch of the immune system is facilitated by all of 
these T cells. HIV ravages the immune system by directly and indirectly targeting and 
attacking the T cells (specifically CD4+ T cells), dendritic cells, as well as macrophages. 
The CDC's classification system stipulates that when a person's CD4+ T cell count falls 
below 200 per microliter (p.1) blood, that person's cellular immunity is damaged to the 
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extent of it leading to AIDS. Generally, healthy people have between 500 and 1500 
CD4+ T cells per (Barlow & Durand, 2001; CDC, 1993; Hutchinson, 2001; Kalat, 
2000; Margolick et al., 1998; Nowak & McMichael, 1995). 
The immunological weakening consequent to the HIV infection then leads to an 
increased risk of contracting a variety of fatal diseases such as Kaposi's sarcoma (KS), 
Pneumocystis jiroveci pneumonia (Formerly known as Pneumocystis carinii pneumonia 
or PCP), Tuberculosis, Toxoplasmosis, AIDS dementia complex, as well as a variety of 
dangerous fungal, viral, parasitic and bacterial infections. Most of these illnesses are 
termed as opportunistic, because they take advantage of the opportunity of a weakened 
immune system to attack. In individuals with a normal and healthy immune system, these 
conditions and infections are usually kept under control by the very elements of the 
immune system that are weakened and damaged by HIV. Technically a person does not 
die from AIDS but rather a disease or infection contracted because of the vulnerability 
resulting from the disease (Barlow & Durand, 2001; Davison, Kring & Neale, 2004; 
Kaplan & Sadock, 1998; Leigh, Shetty, & Fidel, 2004). The World Health Organization 
(WHO), in 1990, grouped these infections and conditions together in such a manner as to 
create a system that can be utilized to identify the stage in which an individual infected 
with HIV-1 is likely to be. These stages range from Stage I (in which the HIV disease is 
asymptomatic and not yet classified as AIDS) through to Stage V (in which the patient is 
likely to have toxoplasmosis of the brain, candidiasis of the esophagus, trachea, bronchi 
or lungs as well as Kaposi's sarcoma) (WHO, 1990). 
After the individual is infected with HIV, it is expected that a person will develop 
AIDS between 7.3 to 10 years later. The course of the disease varies with several minor 
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health problems starting to develop. Emergence of symptoms occurs anywhere between 
several months and several years after HIV was contracted. The condition, AIDS-related 
complex (ARC), consists of these minor problems such as fever, weight loss, and night 
sweats. AIDS is not diagnosed until one of the aforementioned serious opportunistic 
diseases appears. The expected median survival time after developing AIDS is 9.2 
months, although survival time is significantly increased in those cases where the 
individual undergoes antiretroviral therapy, to as much as 5 years (Morgan et al., 2002; 
Schneider et al., 2005). 
It is also important to note that various types of HIV have been identified. In 
humans, two types of HIV are known. HIV-1 is considered the most prevalent with HIV-
2 linked with most cases in West Africa and India (Hutchinson, 2001). Each HIV cell 
has a genetic structure, which differs for the two types. Furthermore, during the 
replication of the HIV cell, certain mistakes can be made, leading to mutations of the 
original cell. In some instances, these mutated cells are inactive copies; however others 
may be HIV mutants that have an enhanced survival and/ or replication ability. These 
cells become worrisome, as their transmission to other individuals and further mutations 
could ultimately lead to a new viral strain such as HIV-3 (Stine as cited in Hutchinson, 
2001). Furthermore, based on the genetic structures of the HIV cells, researchers have 
been able to identify subtypes. Within the HIV-1 strain, three subtypes are identified: M, 
N, and O. Each of these subtypes can even farther be divided into categories. Group M is 
considered the most prevalent and is further divided into 9 categories or clades, noted as 
A through I (Hutchinson, 2001; Thomson, Perez-Alvarez & Najera, 2002). Of these, 
clades A, B, and C represent the large majority, approximately 86%, of circulating HIV-1 
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variants with B being the most prevalent in Europe, Brazil, Canada, Australia, Haiti, and 
the USA, as well as in South African men who have sex with men (Coplan et al., 2005). 
This information is of most importance when considering the type of HIV testing an 
individual needs to undergo. For example, due to very low prevalence rate of the HIV-2 
strain within the USA (as indicated by epidemiologic data), the CDC (2002) does not 
recommend routine HIV-2 testing, however, in the instance that an individual's HIV test 
returns with a positive screening for HIV, the site will test for both HIV-1 and HIV-2 
strains in the case that epidemiologic risk factors for HIV-2 are present. Furthermore, 
testing for HIV-2 will be conducted if clinical evidence exists for HIV, in the absence of 
a positive test for antibodies to HIV-1, or if the HIV-1 Western blot test exhibits an 
unusual pattern (O'Brien, George, Epstein, Holmberg, & Schochetman, 1992). 
Additionally, since 1992, the Food and Drug Administration (FDA) have required that all 
donated blood be screened for HIV-2 (O'Brien et al., 1992). 
Most often, HIV is transmitted from one individual to another though sexual 
intercourse, but it is readily transmitted via contact with infected blood (e.g., through 
blood transfusion). Unprotected anal and vaginal sex and intravenous drug use are 
considered the most risky behaviors associated with HIV transmission. The CDC (2004a) 
breaks down the estimated number of cases diagnosed according to transmission category 
(Table 1). 
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Table 1 
Estimated numbers of cases of HIV/AIDS, by year of diagnosis, population and 
transmission category. 
Year of diagnosis 
2001 2002 2003 2004 
Male adult or adolescent 
Male-to-male sexual contact 16,625 16,852 16,804 18,203 
Injection drug use 5,171 4,379 4,177 3,828 
Male-to-male sexual contact 
and injection drug use 1,525 1,431 1,398 1,372 
Heterosexual contact 5,095 4,843 4,720 4,581 
Other 214 183 179 161 
Female adult or adolescent 
Injection drug use 2,877 2,408 2,252 2,134 
Heterosexual contact 9,192 8,709 8,248 8,102 
Other 211 187 205 174 
Child (<13 years at diagnosis) 
Perinatal 306 245 186 145 
Other 54 44 18 32 
Total 41,270 39,280 38,188 38,730 
Based on statistics concerning the transmission of AIDS in the USA, the 
frequency of the various means of transmission in 2004 is the following: 43% of cases 
were contracted by male-to-male sexual contact; 25% contracted by injection drug use; 
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25% contracted by heterosexual contact; and, the remainder through male-to-male sexual 
contact and injection drug use, hemophilia, blood transfusion, perinatal, and risk factors 
not reported or not identified (CDC, 2004a). 
Using confidential name-based HIV infection reporting, the CDC (2004a) breaks 
down the estimated number of cases diagnosed, deaths associated to AIDS, and 
individuals living with AIDS in the USA's 35 areas. Table 2 lists these estimated 
numbers accordingly for the years 2000 until 2004. 
Table 2 
Estimated numbers of new diagnosis of HIV/AIDS, AIDS related deaths and individuals 
living with AIDS, by year. 
Year 
2000 2001 2002 2003 2004 
AIDS diagnoses 39,513 39,060 40,670 41,831 42,514 
AIDS deaths 17,139 17,611 17,544 17,849 15,798 
Individuals living 
with AIDS 320,177 341,773 364,496 388,477 415,193 
Based on tracking by the CDC, there was an 8% decrease in the estimated number 
of AIDS deaths from 2000 to 2004; during the same time frame; however, the number of 
cases of individuals diagnosed with AIDS increased 8% (CDC, 2004a). Approximately 
40,000 persons become infected every year when one considers all 50 states (Glynn and 
Rhodes, 2005). The increased number of individuals living with AIDS in the USA is 
attributed to the fact that better treatments are available and there has been an increase in 
10 
the use of intensive antiretroviral therapies (Palella et al., 1998; Schneider et al., 2005). 
When one considers the anonymous, almost unobtrusive origins of AIDS in the early 
1980s, it appears that the cases of the disease occurring in seemingly isolated segments of 
society have transformed into one of the major threats to global health. 
HIV Testing 
HIV tests are used to detect antibodies and antigens, as well as ribonucleic acid 
(RNA) in various specimens (serum, blood plasma, oral fluid, dried blood spot or urine). 
In the USA the initial test used to detect the presence of antibodies, the cells created in a 
response to the infection, is the Enzyme-Linked Immunosorbent Assay (ELISA) method. 
In the event that this initial test detects antibodies, a second test, based on the Western 
Blot method, is utilized. The antibody test is then reported as either being positive or 
negative. The performance of these tests is described by considering the test's sensitivity 
(the percentage of results that are positive when HIV is present) as well as its specificity 
(the percentage of the results that are negative when HIV is not present). In the USA, this 
two-test approach is used, claiming to have a 99.5% accuracy rate, which translates into 
500 false positive results (result indicating HIV is present, when it is not) for every 
100,000 people not infected with HIV who are tested. False negative results (result 
failing to indicate HIV when it is present) are most common during the window period, 
or the time between when the infection occurs and the test can first detect a change in the 
body. Antibody tests have an average window period of 22 days. (US Food and Drug 
Administration [FDA], 2006) 
Antigen testing decreases the window period to about 16 days. This method is 
routinely used to screen blood donations; however it is not utilized otherwise for 
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diagnostic purposes as it has a very low sensitivity and is only reliable during a specific 
time: before antibodies are produced by the body. Since 2001, Nucleic Acid based testing 
has become the preferred testing method for blood donations, as it shortens the window 
period to 12 days. Although this method is relatively expensive, a version of it is used for 
the clinical management of HIV infected patients. 
Currently, several different tests for HIV have been approved by the Food and 
Drug Administration (FDA) of the USA's government. The tests differ on the type of 
specimen that is needed to perform the test, such as plasma, a dried blood spot, serum, 
oral fluid, whole blood (venipunctured and fmgerstick), or urine. Additionally, these tests 
vary based on the complexity of the test, the strains of HIV it can detect, and the time it 
takes for the results to become available. Table 3 lists the various types of HIV tests that 
have gained FDA approval (CDC, 2001; FDA, 2006). 
Table 3 
FDA approved HIV tests 
Specimen 
collected 
Test 
complexity 
Time before 
results available 
Standard HIV test 
Rapid Tests 
Serum or plasma 
Serum, plasma, 
whole blood 
High 
Moderate 
few days 
10-60 min 
Home sample collection Dried blood spot High 3-7 days 
Oral fluid test Oral Mucosal Transudate High 1 -2 weeks 
Urine based Urine High 1-2 weeks 
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Researchers are continuously attempting to expand on the ELISA as well as 
Western Blot testing methods and, by doing so, add to the list of FDA approved HIV 
tests. A recent addition to the repertoire of HIV tests is the rapid tests. Four rapid tests are 
currently approved by the FDA: Oraquick Rapid HIV-1, Uni-Gold Recombigen HIV test, 
Multispot HIV-1 /HIV-2 Rapid Test and Reveal Rapid HIV-1 antibody test, with two 
being approved for point-of-care sites without a traditional laboratory (FDA, 2006; 
Greenwald, Burnstein, Pincus, & Branson, 2005). Most noticeable is the approval of 
rapid tests with oral fluid. These tests require a specimen of the individual's oral fluid, 
taken by gently swabbing all around both the upper and bottom gums. One example is the 
OraQuick Rapid HIV test for oral fluid, which was approved in 2004, research indicating 
a 99.3% sensitivity and 99.8 % specificity. However, rapid testing can also be performed 
on other specimens such as whole blood, plasma or serum (CDC, 2004b). 
Although these tests are generally less invasive and results are available in less 
than 20 minutes, in the cases where the client has a reactive test result (indicating an HIV 
positive status), a second confirming test, taking approximately 7 to 10 days, will still 
need to be done (Liang et al., 2005). Liang et al. (2005) found that among 461 clients 
tested at a mobile STD/ HIV clinic, 64.5% preferred OraQuick to traditional serologic 
testing. Notably, however, the clients were not surveyed as to the reason they made their 
choice of a particular HIV test. Poses (as cited in Kane, 1999) points out that a division 
has emerged in the field as concerns the use of rapid testing because, while some clients 
will within minutes be correctly informed of their HIV status, others may experience 
unnecessary anxiety due to false positive results. On the other hand, rapid testing 
increases the number of people who are aware of their true HIV status by giving them 
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feedback before they return home and is of particular benefit in situations of potential 
occupational exposure to HIV (Kane, 1999). Greenwald et al. (2006) argues that when 
rapid testing is compared to standard two-session HIV-testing, rapid HIV testing both 
decreases costs and increases the number of people receiving their results. 
Home testing is another recent trend in HIV testing. The FDA approved the first 
home test kit in 1996, and these can be purchased in some drug stores, over the Internet, 
or by mail. These tests require that the individual draw his or her own blood sample by 
means of a finger prick at home, mail the sample to a laboratory, and call for the results 
approximately 7 to 10 days later (Worthington, 2001). A study by Colfax et al. (2002) 
indicated that despite the manufacturer's anticipation that a large amount of individuals 
would utilize this testing method, the overall sales of home-based kits was relatively low, 
representing approximately 1% of the HIV test performance in the USA that year. 
Individuals who were aware of the tests availability cited concerns about accuracy, lack 
of in-person counseling, and cost as reasons for not using this method (Colfax et al., 
2002). When considering the use of rapid testing it is noteworthy to cite the influence of 
utilizing this method of testing in order to curb the frequency of individuals who fail to 
return for their HIV test results. Keenan and Keenan (2001) suggested that by using rapid 
testing it ensured that same-day results were given to all but one of the individuals tested, 
resulting in a 0.1% failure to return rate. A study by Sullivan et al. (2004) also indicated 
that the availability of rapid testing significantly reduced the failure to return. 
HIV Testing Behavior 
Taking into consideration the shockingly large number of AIDS cases worldwide, 
a potentially more alarming fact is the sheer amount of individuals who either have never 
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had their HIV status tested or who have been tested and failed to return for their results. 
Janssen et al. (2001) estimated that approximately one third of the USA's residents who 
are currently infected by HIV are unaware of their seropositive status, stating therefore 
that an approach to reducing HIV incidence in the USA would be to increase the number 
of HIV-infected persons who are aware of their serostatus, thereby creating an 
opportunity for their adoption of behaviors limiting the probability of HIV transmission 
to others (Janssen et al., 2001). In a study that included 512 individuals who received 
HIV testing, Hightow et al. (2003) found that nearly 55% of people in the sample failed 
to return to determine their HIV status and 58% of the non-returning individuals were 
HIV positive. Furthermore, the study indicated that it took a median of 12 days for 
disease intervention specialists to locate the infected individuals. Similar results were 
reported by Dinh et al. (2005) in a study of 500 pregnant women in Vietnam, which 
indicated that only 53.2% accepted HIV testing when offered and, of those, only 55.3% 
returned for their results. 
A national quantification of these behaviors can be seen when considering data 
from the approximately 2.5 million HIV tests that are administered each year in the USA, 
indicating that a staggering amount of individuals failed to return for their results. 
Furthermore, of those individuals who failed to return for their HIV test results, 25% had 
tested positive and 33% tested negative (Anderson, Chandra, & Mosher, 2005). 
Considering the area from which participants for this study will be recruited, a discussion 
of the incidence of germane HIV-testing relevant behaviors is warranted. Aggregate 
figures indicate that 41% of the individuals tested, failed to return for their results 
(Kentucky Department for Public Health, HIV/AIDS Branch, 2006). 
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Regarding the greater community around Western Kentucky University (WKU) 
information on HIV testing behavior was obtained from Carrie Halcomb, the Health 
Educator of the Community Health Promotion Team 1 from Barren River District Health 
Department in Bowling Green, KY. According to Ms. Halcomb, in Warren County, one 
in 3 individuals who tested positive for HIV failed to return for their results, and 
statewide 16% of the individuals who tested positive failed to return to learn their result. 
The return rates for 2005 for the city of Bowling Green Kentucky indicate that nearly 
two-thirds - fully 64% - of the individuals tested for HIV at the Warren County Health 
Department failed to return to the facility to learn their test results (Halcomb, personal 
communication, December 11, 2006). 
In an interview with the Coordinator of Health Education at the WKU Health 
Services, Kathryn Steward (personal communication, June 20, 2006) explained the 
various HIV testing possibilities for WKU students offered by WKU Health Services. 
WKU students are able to participate in anonymous HIV testing on one of three days 
throughout the school year, during 'Health Day,' 'Sexual Awareness Week' and/or 
'World AIDS Day.' While no official data on these events are collected, it is estimated 
that approximately 40 to 50 students got tested for HIV at each event. Furthermore, Ms. 
Steward estimates that only approximately 20% of those who take an HIV test return to 
receive the results. She attributes this low return rate to two factors: the high number of 
students who participate merely to receive extra credit and the possibility that 
participating students misunderstand the testing situation. Anonymous testing is done in 
such a manner that no identifying information is received from the participant. The 
student is issued a number that coincides with his or her oral test sample. If the student 
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wishes to know his or her results, he or she has to inquire from the appropriate person 
following the HIV test and present the assigned number in order to receive testing results. 
However, some students may fail to realize that it is their responsibility to follow-up on 
the results and assume that if they do not hear from anyone, their HIV test results are 
negative. Students are also able to get tested for HIV status, at their convenience, at the 
student health services during usual operating hours. The test is confidential in nature, but 
students have to request specifically to take the test from the physician. The student then 
needs to be seen for post HIV-test counseling in order to receive the results. 
From the above mentioned statistics, it appears that regardless of the geographical 
region, the failure to return for HIV test results occurs far more often than those 
endeavoring to prevent the spread HIV would desire. A better understanding of attitudes 
related to HIV testing and the results of such testing might be useful in increasing the 
number of individuals who return for the results of serological status testing or the 
number of individuals who take an HIV test in the first place. 
One possible explanation for the exceptionally high rates of individuals who fail 
to return for the results of their HIV testing (or conversely the relatively low rates of 
individuals who get tested in the first place) may be found in the study of avoidance 
behavior. It is likely that the individuals who fail to take an HIV test or fail to return for 
the results are either intentionally or unintentionally avoiding being faced with 
information concerning their personal HIV status. When one initially considers avoidance 
learning, it appears that nothing - that is no explicit contingency - acts as reinforcement 
for a behavior, i.e. a person will continue to do a behavior without tangible reinforcement 
of the behavior. However, one way to resolve the lack of explicit reinforcement in 
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avoidance learning is via a consideration of Mowrer's two-factor theory (Barlow, 2004; 
Klein, 2002; Mowrer, 1947; Mowrer, 1950; Terry, 2006). Mowrer argues that, in 
avoidance learning, a person is not merely behaving because of "nothing"; rather the 
reinforcer is an unobservable thing, i.e. the escape from an acquired fear or negative 
reinforcement. Since avoidance behavior is integral to the discussion of anxiety 
(particularly phobic manifestations of anxiety) there follows an in-depth discussion of 
anxiety and the potential role it may play in HIV testing-related behaviors. 
Anxiety 
The experience of anxiety is considered to be fairly universal; everyone at some 
point in time has been anxious. As a consequence, definitions of anxiety abound. The 
pattern of arousal inherent in anxiety, however, can be defined in terms of psychological, 
physiological as well as behavioral terms. Cannon (1927) coined the flight-or-fight 
response: a physiological reaction to a threat, mediated by the sympathetic division of the 
Autonomic Nervous System, that mobilizes a person to either fight or flee from an 
emerging threat. This state is usually accompanied by physical reactions such as 
increased heart rate, blood pressure and breathing, muscle tension and sweating; this 
same pattern of arousal is seen in the individual expression of anxiety. Both human and 
animal research indicates that the physical symptoms associated with the state of anxiety 
are linked to activity in the central periaqueductal gray and medial hypothalamus, with 
descending control from the amygdala. Physiological changes of arousal are implicated in 
the overt behavioral manifestations of anxiety; sympathetic activation, for example, is 
involved in such observable behaviors as attack posturing, escape maneuvers, active 
avoidance, and even freezing in the presence of anxiety provoking stimuli, whether 
internally or externally cued (Barlow, 2004; Barlow & Durand, 2001; Bourne, 2000; 
Cannon, 1927; Davison, Kring & Neale, 2004; Kalat, 2000; Kaplan & Sadock, 1998). 
Psychologically the experience of anxiety is more difficult to pin down with 
exactitude. When trying to define anxiety most texts also define fear. Although it might 
seem easy to distinguish between fear and anxiety, the distinction between fear and 
anxiety based on the focus of threat or anxiety provoking stimulus can become blurred. 
Several similarities exist between anxiety and fear such as the fact that both include an 
elevated arousal and negative affect usually accompanied by bodily sensations and both 
are a future oriented apprehensiveness about a danger or discomfort. Despite the 
similarities, anxiety and fear can be differentiated (Rachman, 2004). The distinction 
between fear and anxiety arose quite by accident when one of Freud's early translators 
mistranslated the word Angst, the German word for fear, as anxiety. Strictly speaking, the 
term fear refers to an individual's emotional reaction towards a specific, identifiable 
object. Anxiety, on the other hand, is a more unsettling emotional reaction to the 
anticipation of a vague, potential threat. Freud failed to put much emphasis on 
distinguishing fear from anxiety. For Freud, anxiety was related more to an internal, 
unknown object, whereas fear could be due to a repressed, unconscious conflict, 
displaced onto an external object. The latter is best depicted in Freud's discussion of the 
case of Little Hans, who "refused to go out on into the street because he was afraid of 
horses" (Freud, 1959, p. 27). Freud had a theory that the little boy's fear of horses was a 
displaced fear of his father; that is, even though there was an identifiable threat that 
caused Little Hans' fears (i.e. the horse), it was not the object per se but rather an internal 
Oedipal conflict that gave rise to the child's anxiety. In 1926, with the publication of 
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"Inhibitions, Symptoms, and Anxiety," Freud created a new theory of anxiety. He no 
longer regarded anxiety as resulting from an increased libido or a repressed thought or 
wish, but rather as a reaction to dangerous situations. He went further to identify two 
anxiety-provoking situations, the first involving an overwhelming instinctual stimulation, 
as is found during the experience of birth. The second and more common type of anxiety 
resulted from the anticipation of danger or a traumatic event (Freud, 1959; Barlow, 
2004). 
Modern conceptualizations differ greatly from Freud's attempts to explain anxiety 
and fear. Behavioral theories focus on various types of learning, and the role these play in 
acquiring fears. According to most behaviorally based theories, fear is considered to be a 
conditioned response to a specific environmental stimulus (Kaplan & Sadock, 1998). 
Watson and Rayner (1920) demonstrated a classical conditioning approach in their 
experiment with Little Albert, in which a toddler was conditioned to fear white rats by 
pairing a neutral stimulus (the white rat) with an unpleasant experience (a loud and 
aversive noise). Furthermore, experiments in vicarious learning, or learning by 
modeling, strongly suggest that phobic anxiety can be acquired by watching the reactions 
of others to a given stimulus. Cognitive theorists, on the other hand, view anxiety and 
fear as being related to an individual's thought processes. Accordingly, it is a person's 
interpretations of a stimulus that can create the anxiety (Davison, Kring, & Neale, 2004). 
Beck and Clark (1997), for instance, argued that automatic thoughts about the threat, 
which arrived from distorted informational processing, trigger the components of the 
anxiety response, consequently creating the state of anxiety. 
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Despite the terminological confusion and the varied emphases of the different 
theoretical conceptualizations of the origins of fear and anxiety, one fact remains: anxiety 
is a virtually universal experience. It is generally agreed upon that, without some level of 
anxiety, people would probably accomplish very little. The presence of a degree of 
anxiety is considered to be a positive motivational factor in that it provides impetus for 
physical and intellectual performances (Barlow, 2004; Davison, Kring & Neale, 2004; 
Klein, 2002; Yerkes & Dodson, 1908). However, when anxiety is experienced in its 
extreme form, in either its absence or at too great a level, the experience becomes 
abnormal, causing the emergence of an anxiety disorder. 
Two-factor Theory of Anxiety. The rise of behavioral therapy during the 1950 and 
60's and the successes of specific behavioral techniques in the treatment of those with 
phobias awakened an interest in the ways in which learning processes, such as 
conditioning, were involved in the acquisition of anxiety. The earliest paradigm of 
learning processes in the development of anxiety was best exemplified by Watson and 
Rayner's conditioning of the fear of a white rat in Little Albert; needless to say, this 
illumination of a learned fear focused exclusively on classical conditioning (Barlow, 
2004; Klein, 2002; Watson & Rayner, 1920). 
Mowrer in 1947, proposed the "two-factor theory," a modification of anxiety 
acquisition that extended beyond simple classical conditioning. The two-factor theory 
uses classical conditioning to argue that avoidance is really just an escape from an 
acquired fear of a specific warning stimulus. Mowrer suggested that a warning stimulus 
might be regarded as a conditioned stimulus because of its relation to an unpleasant event 
that an organism later wants to avoid, but which is at first administered together. The 
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warning stimulus then produces fear, which may be seen as a classically conditioned 
response (or affective state) or can be seen in light of physical behaviors associated with 
the activation of the autonomic nervous system. Reinforcement occurs when the 
instrumental response reduces the fear by terminating the warning stimulus. So actually, 
avoidance behavior is an escape response moved forward in time. The subject may be 
regarded as escaping from the fear created by the warning stimulus rather than from the 
unpleasant event that it has learned to fear (Klein, 2002; Terry, 2006). 
When considering the role of the two-factor theory in developing and 
maintaining phobias, Mowrer suggested that the anxiety characteristic of phobia is 
acquired in two stages. Firstly, the fear becomes conditioned to the environment that 
precedes the aversive situation. Secondly, the person then learns an "instrumental or 
operant behavior that will successfully terminate the feared stimulus" (Klein, 2002, p. 
167). Although Mowrer acknowledged the role of classical conditioning and its primacy 
in the acquisition of phobic anxiety, he hypothesized that avoidance learning was critical 
in the maintenance of anxiety (Klein, 2002; Mowrer, 1947). He suggested that a phobia 
will "fail to extinguish if one successfully learns to avoid the feared stimulus" (Barlow, 
2004, p. 236). The phobia causes an escape and/or avoidance of the feared thing or 
situation and this negatively reinforces the person's behavior when faced with the same 
event or situation in future. This inability to extinguish the tie between the feared 
stimulus and the avoidance response results is what Mowrer called the "neurotic 
paradox." Mowrer describes this as "the paradox of behavior which is at one and the 
same time self-perpetuating and self-defeating" (Mowrer, 1950, p. 486). For Mowrer 
people should optimally and rationally consider and weigh out the consequences 
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associated with their behavior. In the event that the outcome of such a consideration is 
favorable, the behavior should be continued; however, if the outcome is unfavorable, the 
behavior should be stopped. Moreover, he argues that most people are aware that, in the 
situations they avoid, there is nothing of which to be fearful in reality and that an accurate 
appraisal of their options between a favorable and unfavorable behavior should lead to an 
abandoning of avoidance behaviors. Despite the possibility for this cognitively mediated 
weighing process, however, most phobic individuals fail to stop their self-defeating 
behavior (Barlow, 2004; Mowrer, 1947; Mowrer 1950). Employing defense mechanisms 
to alleviate the anxiety further facilitates the behavior of avoiding or escaping. 
Defense Mechanisms. Relevant to a discussion of anxiety, it is important to 
understand what happens when an individual experiences overwhelming amounts of 
anxiety generally from a non-identifiable or internally cued source. Stemming from 
Freud's perspective on anxiety, defense mechanisms are viewed as means of anxiety 
reduction deployed, at an unconscious or automatic level, in any of the following 
conditions: when the id impulses are in conflict either with one another or with the 
superego, or when an external threat is posed to the ego (Freud, 1937). Anna Freud 
greatly extended upon Freud's definition of defense mechanisms in the Ego and 
Mechanisms of Defense, published in 1936. Defense mechanisms were conceptualized 
either as intrapsychic mechanisms that distort the id impulses into an acceptable form or 
that block id impulses from conscious awareness. The work of both Sigmund and Anna 
Freud posited a variety of different defense mechanism, many of which have entered into 
everyday language, such as denial. Some defense mechanisms are considered to be more 
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adaptive or healthy than others. Freud considered sublimation to be the most productive 
defense mechanism as opposed to the others he identified (Cramer, 2006; Freud, 1937). 
Currently, the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, 
Text Revision (DSM-IV-TR) offers a more behaviorally explicit and less theoretically 
bound definition of defense mechanisms as "automatic psychological processes that 
protect the individual against anxiety and from awareness of internal or external dangers 
or stressors" (American Psychiatric Association [APA], 2000). Examples of defense 
mechanisms include regression (where an individual reverts back to an earlier stage of 
development) or intellectualization (where an individual concentrates on the intellectual 
components of a situation in order to distance him/herself from the emotions associated 
with the situation). It is generally accepted that defense mechanisms are healthy and 
helpful coping mechanisms, although there are instances where these mechanisms can 
serve a maladaptive purpose. Such is the case when the employment of the defense 
mechanism leads to a chronic avoidance of or delay in taking necessary action. For 
example, denying the possibility of being exposed to HIV will lead a person to avoid 
taking a HIV test. 
Anxiety and related disorders. According to a study by Kessler et al. (1994), 
anxiety and its related disorders are among the most common mental health concerns. In 
fact, because of the variety of the ways in which anxiety can impact an individual, there 
has been a continued trend toward a greater diagnostic specificity in the arena of anxiety 
disorders. Within the Diagnostic and Statistical Manual, considerable changes have taken 
place throughout the years, resulting in the growing length and specificity of each new 
edition (Rogler. 1997). The number of anxiety related disorders, for example, has 
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increased in every edition of the Diagnostic and Statistical Manual and each subsequent 
edition has emphasized a greater behavioral specificity of the disorders grouped within 
that category. Such is the case with specific phobia, defined by the DSM-IV TR (APA, 
2000) as the excessive, unreasonable, and persistent anxiety triggered by an object or 
situations. 
Anxiety disorders are diagnosed by criteria set forth in the DSM-IV-TR. Seven 
principle diagnoses have been identified: Panic Disorder, Agoraphobia, Specific Phobia, 
Generalized Anxiety Disorder (GAD), Obsessive-Compulsive Disorder, Posttraumatic 
Stress Disorder, and Acute Stress Disorder. All these disorders are predicated upon 
clearly present feelings of anxiety (APA, 2000). The feelings of anxiety differ, however, 
across the spectrum of anxiety disorders. Phobic anxiety differs from the experience of 
anxiety in disorders such as Generalized Anxiety Disorder, Agoraphobia, and Panic 
Disorder. For example, in the instance of a specific phobia, anxiety is manifested only in 
the presence of the phobic object or situation; on the other hand, in GAD, anxiety is 
almost always present in the form of worry and is in fact not focused on any specific 
context or object. Until the fourth publication of the Diagnostic and Statistical Manual, in 
1994, there was no meaningful classification within the area of specific phobias (Barlow 
& Durand, 2001; Rogler, 1997). Currently, the areas of specific phobias are categorized 
by the DSM-IV-TR as animal, natural environment, blood-injection, and situational type. 
Each of these types consists of various stimuli that become the focus of the anxiety. For 
example, in Blood-and-Injection phobia, the individual's experience of anxiety is cued by 
seeing an injury or blood or by receiving an injection (APA, 2000). Following is a brief 
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discussion on some of the specific stimuli that could trigger feelings of anxiety in 
individuals as they may pertain to the topic of HIV testing. 
Anxiety and HIV Testing 
When applying the information with regards to anxiety to the specific case of HIV 
testing, I argue that the possible fears associated with the situation can include, but are 
not limited to, medical and death anxiety. 
The fear of death is guided by several theories. Becker (1973) argues that all 
living things share the drive to continue existing, and that the human brain is the most 
successful survival mechanism. In addition, he also states that the fear of death is natural 
and it is present in everyone. As soon as the individual is able to think, he or she will 
realize the drive to continue existing as well as the fact that he or she will die. To Becker 
this contradiction is at the root of our human anxiety (Liechty, 2000). Firestone (1993) 
states that despite the fact of our mortality, individuals generally deny or displace their 
fear of death in order to continue functioning everyday without being overwhelmed by 
the anxiety caused by the knowledge or foreknowledge of their own demise. The various 
defenses used to manage the anxiety of death are apparent in a study by Ford, Ewing, 
Ford, Ferguson and Sherman (2004). Those college students who were primed for anxiety 
associated with death by first completing death anxiety measure as opposed to 
completing the death anxiety measure at the end of the session, were found to exhibit a 
denial-based defensive activity which correlated with a significant increase in self reports 
of a willingness to engage in high-risk sexual behavior. Safren, Gershuny, and 
Hendriksen (2003) found that, when controlling for variables of depression and the 
satisfaction with social support, death anxiety was still associated with overall Post-
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Traumatic Stress Disorder (PTSD) symptoms among patients with HIV. They argue that 
receiving the diagnosis of HIV is a chronic stressor similar to the trauma experienced by 
individuals who develop PTSD. 
Medical anxiety is similar to the widely researched dental anxiety and refers to a 
context-specific anxiety related to aversive affect and anxiety related avoidance in 
various medical and healthcare situations. Prior research investigating the impact of 
dental anxiety on behaviors such as routine checkups and more invasive dental 
interventions has consistently shown a strong association between dental fear and delay 
in or avoidance of treatment (Abrahamsson, Berggren, Hallberg & Carlsson 2002; Corah, 
O'Shea, & Skeels, 1982; Kleinknecht & Bernstein, 1978). Limited research into the 
connection of medical fear and healthcare behaviors suggests that patients who express 
high levels of medical anxiety are more likely to delay receiving treatment for an acute 
and life-threatening medical concern (e.g., angina) than are individuals with lower levels 
of medical anxiety (Fowler, 1996). When considering the HIV testing process, various 
potentially anxiety provoking stimuli can be identified such as that the individual to be 
tested may be exposed to various medical procedures (e.g. blood being drawn), the 
general healthcare situation (e.g. discussing results with a physician) as well as medical 
concepts (e.g. germs and disease). 
It is likely that anxiety related to HIV/ AIDS shares many commonalities with 
specific phobias, in that at least some of the anxiety elicited by HIV/ AIDS is bound to a 
specific stimuli or contexts, such as death and medical anxiety. For example, being 
fearful of medical procedures, such as blood drawing required by a number of HIV tests, 
or being fearful of contracting the actual disease both may serve as factors preventing 
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individuals from getting their serological status checked in the first place or causing them 
to fail to return. However, beyond specific phobias, HIV testing also likely elicits 
broader based anxieties such as the anxiety surrounding death: a positive HIV test, 
assuming its accuracy, is ultimately a death sentence and likely to evoke deep fears in the 
individual being tested. Employing Mowrer's two-factor model, people's avoidance of 
being tested and their failure to return for HIV test results can be seen as behaviors of 
escape and avoidance, not just of the situation surrounding HIV testing, but also of the 
feared stimulus, AIDS, as well. The behavior of individuals (particularly those engaged 
in high-risk activities) who avoid testing becomes self-defeating, as an early diagnosis 
and treatment of HIV could extend their lives and the moral anxieties about inadvertently 
spreading the disease could be eliminated by an accurate knowledge of HIV status. 
Despite compelling reasons to be tested, many individuals avoid being tested. 
Despite the distinct possibility that anxiety plays a role in decisions concerning 
HIV testing - for example, as a causal factor influencing failure to return for the results 
of HIV testing - an extensive literature review yielded no study that specifically 
examined the association between anxiety and HIV testing behavior. Moreover, even 
finding studies that make mention of the possible role of anxiety in individual attitudes 
toward facets of HIV testing are far and few between, with most of the focus to date 
falling on samples drawn from outside the USA or consisting of individuals who have 
already tested HIV positive. One such study by Buckingham (1987) addresses the unique 
concerns of women and AIDS. The article suggests that those women who test positive 
for HIV have a heightened anxiety, hence retreating into defense mechanisms, such as 
denial, and becoming preoccupied with maintaining health. 
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Anxiety experienced specifically within the HIV testing situation is briefly 
mentioned in a study by Sullivan et al. (2004) in which self-reported failure to return 
amongst high-risk persons revealed that, if during pretest counseling. There is an 
increased focus on the individual's fear of learning their HIV status, this ultimately leads 
to a significant reduction in the frequency of failure to return. Lyter at al. (1987) 
examined the reasons gay and bisexual men decided whether or not to receive their HIV 
test results. The researcher invited 2047 men who previously enrolled in the Pitt Men's 
Study by mail asking them whether they would want to learn their HIV test results. 
Additionally, they were asked to complete a questionnaire to assess, amongst other 
variables, their reason for wanting to know or not know the results. Those who indicated 
they wanted to know their status were seen by a clinician. Of the participants, 54% 
learned their results, 7% indicated they wanted to receive their results but failed to meet 
the clinician for a disclosure meeting, 9% formally declined to receive their results and 
the remaining 30% of the participants failed to respond to the invitation. Of those gay or 
bisexual men who declined to be informed of their status, 31% cited concern about the 
harmful psychological impact a positive result might have on them. Forty-eight percent 
of the respondents indicated that "a positive test result would be too worrisome, and 28% 
believed that if their results were positive they would be "afraid to have sex" (Lyter et al., 
1987, p. 471). Worthington and Myers (2003) explores the social and situational factors 
underlying anxiety during diagnostic testing. Information from interviews with 41 test 
recipients was analyzed and four main themes related to anxiety were identified. 
Throughout the interviews, participants identified themes of perception of risk and 
responsibility, the social experience of HIV and stigma, the patient-provider power 
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dynamic, and techniques used by test recipients to enhance a sense of control in the 
interaction between self and the provider. The authors go on to discuss practical 
implications for providers, such as explicitly addressing a patients anxiety over perceived 
risk; reinforcing testing behavior, promoting further health changing behavior, and the 
importance of test provider's demeanor' and behavior during testing. 
More studies can be found that discuss anxiety and fear of HIV/AIDS in a more 
general sense and not only limited to the testing situation. Attitudes and feelings related 
to HIV/AIDS were studied by Kaijaleena and Aavarinne (1999) in a study in which 245 
university students in Finland were assessed on their attitudes and feelings towards 
HIV/AIDS. Respondents in this study expressed more negative and intensive feelings 
towards AIDS than HIV, with fear about HIV being linked to the fear of contracting 
AIDS. Additionally, students identified feelings of fear towards HIV/ AIDS such as 
fearing AIDS because it leads to death and fearing contracting HIV as it was "unfair and 
as a factor limiting people's sexual behavior" (Kaijaleena & Aavarinne, 1999, p. 466). 
Waldner, Sikka, and Baig (1999) list several studies with regards to the fear of AIDS, 
stating that in the past it has been established that the fear of AIDS is linked to the fear of 
casual contact with another person who has AIDS rather than a fear of personally 
contracting AIDS. Goodwin & Roscie (as cited in Waldner et al., 1999) found in a 
sample of 109 university students in the Southwestern USA that the fear of AIDS is 
higher amongst men than women. Furthermore, the study established that AIDS 
knowledge varies across different ethnical groups, with African Americans having the 
lowest scores. AIDS knowledge is important inasmuch as past research suggests a link 
between AIDS knowledge and fear of AIDS. For example, Chliaoutakis and Trakas 
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(1996) collected data from 1552 respondents in Attica, Greece and found that the higher 
the level of AIDS knowledge, the lower the level of discrimination and stigmatization. 
Furthermore, the researchers attempted to understand the relationship between AIDS and 
fear by looking at underlying factors, and although they argue that risk perception may 
play a part, this did not appear to make sense in all the cases. Due to the paucity of prior 
research, I believe that an examination of the role of anxiety and defense mechanisms and 
the ways in which anxiety is involved in avoidance behaviors can provide a deepened 
understanding of the reasons underlying avoidance of HIV testing and the failure to 
return for HIV test results. 
Current Study 
Recent numbers estimate that in the U.S.A. about 1 million people are living with 
HIV or AIDS. Of these individuals, approximately 250,000 are unaware of their infection 
(CDC, 2005). In an attempt to understand why there is such a vast amount of infected 
people unaware of their HIV status, one can possibly explain this by looking at current 
HIV testing behavior as it is reported in the USA's population. During the year 2002, 
approximately half of all men and women between 15-44 years of age reported that they 
had been tested at least once for HIV, which leaves the other half of the population as 
never being tested (Anderson, Chandra, & Mosher, 2005). Furthermore, studies suggest 
that typically about half of the individuals who do take a HIV test fail to return for the 
results of their test (Dinh et al., 2005; Hightow et al., 2003; Strauss et al. 2002; Sullivan 
et al., 2004). These statistics about HIV testing behavior indicate that an alarming number 
of individuals are likely to remain ignorant of their HIV status, either due to not having 
their HIV status tested at all or a failure to return to receive the results of FIIV testing. 
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This research examined the role anxiety plays in individual decision-making concerning 
HIV testing behavior. Due to the high probability that being tested for a life-threatening 
disease provokes anxiety, it was hypothesized that anxiety influences the likelihood both 
of submitting to an HIV test in the first place and of returning for the results of HIV 
testing after one has decided to be tested. 
The concept of anxiety is both broad and multifaceted; therefore, the research 
examined the relationship of both broad-based anxiety and more domain-specific (or 
narrow-band) types of anxiety and attitudes about HIV testing behavior. At its broadest 
iteration, I assessed trait-based anxiety and the physical, cognitive, and affective 
symptoms generally associated with anxiety disorders. The domain-specific types of 
anxiety investigated were facets of medical-context anxiety (specifically those related to 
germs, the hospital environment, medications, and Blood/Injection/Injury), Death 
anxiety, and AIDS-Specific anxiety. The role of each of these types - or contexts - of 
anxiety, individually or in combination, was examined vis-a-vis its impact on HIV testing 
behavior. 
Hypotheses. Prior research and speculations based on theory permit basic 
hypotheses as to how the above mentioned independent variables would impact the two 
dependent variables: the likelihood to being tested for HIV or the likelihood to return for 
HIV tests results. Hypotheses for each of the dependent variables are presented below. 
Hypotheses concerning the Likelihood of Being Tested for HIV Status: 
1. Higher levels of General anxiety, as measured by both the state and trait-versions 
of the STAI, will be associated with lower levels of the likelihood to acquire HIV 
status. 
2. Higher levels of endorsement of anxiety related symptoms, as measured by the 
SAS, will be associated with lower levels of the likelihood to acquire HIV status. 
3. Higher levels of AIDS-Specific anxiety, as measured by the MAAQ, will be 
associated with lower levels of likelihood to acquire HIV status. 
4. Higher levels of Blood/Injection/Injury anxiety, as measured by the B/I/I subscale 
of the MAS, will be associated with lower levels of the likelihood to acquire HIV 
status. 
5. Higher levels of Germs anxiety, as measured by the Germs Subscale of the MAS, 
will be associated with lower levels of the likelihood to acquire HIV status. 
6. Higher levels of anxiety about taking medications or pharmacist error, as 
measured by the Medications and Pharmacist subscale of the MAS, will be 
associated with lower levels of likelihood to acquire HIV status. 
7. Higher levels of anxiety about being in the hospital or having to undergo 
treatment in a medical center, as measured by the Hospital and X-Ray Anxiety 
subscale of the MAS, will be associated with lower levels of likelihood to acquire 
HIV status. 
8. Higher levels of Death anxiety, as measured by the DAS, will be associated with 
lower levels of likelihood to acquire HIV status. 
Hypotheses concerning the Likelihood of Returning for HIV Test Results. 
1. Higher levels of General anxiety, as measured by both the state and trait-versions 
of the STAI, will be associated with a higher likelihood of failure to return for 
HIV test results. 
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2. Higher levels of endorsement of anxiety related symptoms, as measured by the 
SAS, will be associated with a higher likelihood of failure to return for HIV test 
results. 
3. Higher levels of AIDS-Specific anxiety, as measured by the MAAQ, will be 
associated with a higher likelihood of failure to return for HIV test results. 
4. Higher levels of Blood/Injection/Injury anxiety, as measured by the B/I/I subscale 
of the MAS, will be associated with a higher likelihood of failure to return for 
HIV test results. 
5. Higher levels of Germs anxiety, as measured by the Germs Subscale of the MAS, 
will be associated with a higher likelihood of failure to return for HIV test results. 
6. Higher levels of anxiety about taking medications or pharmacist error, as 
measured by the Medications and Pharmacist subscale of the MAS, will be 
associated with a higher likelihood of failure to return for HIV test results. 
7. Higher levels of anxiety about being in the hospital or having to undergo 
treatment in a medical center, as measured by the Hospital and X-Ray anxiety 
subscale of the MAS, will be associated with a higher likelihood of failure to 
return for HIV test results. 
8. Higher levels of Death anxiety, as measured by the DAS, will be associated with a 
higher likelihood of failure to return for HIV test results. 
Study Design. The design of the study was passive observational/correlational. The 
study examined how a group of independent variables (namely, various types of anxiety) 
impact two separate dependent variables: likelihood of acquiring HIV status (via being 
tested) and likelihood of returning for results of the HIV status testing. Furthermore, this 
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study controlled for certain extraneous variables that have been identified as potentially 
impacting HIV testing behavior. 
The dependent variables for this study were identified as the Likelihood of Being 
Tested for HIV and the Likelihood of Returning for HIV Test Results. The independent 
variables for this study were identified as General anxiety, AIDS-Specific anxiety, 
Blood/Injection/Injury anxiety, Germs anxiety, Hospital and X-Ray anxiety, Medications 
anxiety, and Death anxiety. The extraneous variables identified for this study were 
gender, ethnicity, relationship status, previous HIV testing behavior, past sexual history, 
HIV related knowledge, current HIV risk and personal experience of HIV/ AIDS. 
Method 
Participants 
Participants were 347 students in introductory or advanced-level psychology 
classes attending Western Kentucky University. Of the original sample of participants, 
five participants were removed from the sample due to excessive missing data. These 
participants failed to answer the questions adequately, leaving their questionnaire with 
more than 25% missing data. The final sample retained 342 participants. Participants 
were recruited in psychology classes and received either the research credit required for 
the class or extra credit for their participation in the study. There were 129 (37.7%) male 
participants and 208 female (60.8%) participants. Regarding ethnicity, there were 293 
(85.7%) Caucasian participants, 24 (7%) African-American participants, 12 (3.5%) Asian 
participants, 8 (2.3%) Bi-Racial or Multiracial participants, 2 (.6%) Hispanic or Latino 
participants, 2 (.6%) Native American or Alaska Native participants and 1 (.3%) Native 
Hawaiian/ Pacific Islander participant. Regarding the participant's educational level, 
there were 186 (54.45) participants who classified themselves as first-year college 
students, 69 (20.2%) who endorsed themselves as second-year college students, 48 (14%) 
as third-year college students, and 38 (11.1%) who endorsed themselves as fourth-year 
college students. With regards to the participant's relationship status, 134 (39.2%) 
participants reported being single, 161 (47.1%) participants reported being in a 
relationship, 12 (3.5%) were living with their partners, 18 (5.3%) were engaged, and 16 
(4.7%) reported being married. When queried about prior sexual activity, 251 (73.4%) 
reported that they have been sexually active, and 87 (25.4%) reported that they had never 
been sexually active. Regarding a history of HIV testing, 60 (17.5%) participants 
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reported that they had previously taken a HIV test, and 282 (82.5%) reported no prior 
HIV testing. Five participants (1.5%) did not indicate their gender, 1 (.3%) participant 
failed to indicate his/her current school year, 1 (.3%) participant did not indicate 
relationship status, and 4 (1.2%) participants failed to respond to the item concerning past 
sexual history. 
Measures 
Vignettes. For the purpose of this study, the researchers created a vignette about 
HIV testing. The vignette asked participants to imagine that they are able to receive a 
HIV test today that will be free of charge, anonymous, and tailored to their expectations 
(i.e. they can pick the specimen, test type, result time frame, etc.). The participants were 
asked to rate the likelihood that they would take the HIV test if the prescribed parameters 
obtained as well as rating the likelihood that they will return to receive the HIV test 
results (See Appendix A). Participants were asked to rate the likelihood of engaging in 
these HIV testing-related behaviors on a ten-point Likert-type scale on which a rating of 
"1" would indicate that they are "not likely at all," a rating of "5" would indicate that 
they are "somewhat likely," and a rating of "10" would indicate that they are "extremely 
likely" to act in the described manner. Responses on these two scales were used as the 
dependent variables during the stepwise multiple regressions. 
Demographics. Participants were asked to provide information regarding 
demographics (such as age, ethnicity, etc.), relationship history, and HIV/AIDS related 
information. Research suggests that certain factors are associated with an increased 
likelihood of failing to return for HIV test results. For example, Hightow et al. (2003) 
found that failure to return was more common among African Americans and individuals 
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with a prior history of failure to return. Considering the potential role of demographic 
variables, participants were asked to answer questions concerning their gender, age, 
ethnicity, and current school year, as well as the highest educational level achieved by 
their mother and father (See Appendix B). Furthermore, each participant was asked to 
answer questions pertaining to personal relationship history, including information 
concerning marital status, sexual orientation, and whether he or she has a history of being 
sexually active (See Appendix C). Additionally, participants answered questions relating 
to HIV/ AIDS and HIV testing (See Appendix D). Specifically, each participant was 
asked whether she or he personally knows or has known someone with HIV/AIDS. Prior 
research has suggested that such HIV-related factors as knowing someone with 
HIV/AIDS influences the HIV-related attitudes as well as the likelihood of having HIV 
status tested (Macintyre, Brown & Sosler, 2001; Camlin & Chimbwete, 2003). 
Additionally, since past experience with HIV testing as well as the objective 
characteristics of the testing context have been associated with the failure to return for 
HIV testing (Keenan & Keenan, 2001; Sullivan et al., 2004) each participant was also 
asked questions concerning his or her past HIV testing behavior, such as whether he or 
she had ever taken an HIV test and whether or not he or she knew his or her own HIV 
status. The participant's responses to these questions were used for descriptive statistics 
as well as to control for extraneous variables. 
State-Trait Anxiety Inventory. The State-Trait Anxiety Inventory (STAI; 
Spielberger, Gorsuch, Lushene, Vagg, & Jacobs, 1983) consists of two 20-item self-
report measures that assess state and trait levels of anxiety. Standardized administration 
involves administering the state version prior to the trait version. Respondents indicate 
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how much each statement reflects how they feel right now, at this moment (state version), 
or how they generally feel (trait version) on four-point Likert-type scales. Participants are 
expected to rate these statements by indicating either a 1 if the statement is 'not at all' 
like them, a 2 if it is 'somewhat' like them, a 3 if it is like them 'moderately so,' and a 4 
if the statement is 'very much so' like them. Sample items from the state version include 
"I feel frightened" and "I feel pleasant." Sample items from the trait version include "I 
wish I could be as happy as others seem to be," "I am a steady person," and "I have 
disturbing thoughts." Both scales can be administered in 10 minutes. Anxiety-absent 
items on each scale are reverse-scored, and the 20 items of each scale are then summed 
for total scores. Scores can range from 20 to 80, with a higher score indicating higher 
levels of anxiety. The STAI shows good to excellent internal consistency for both scales 
(alphas between .86 and .95) in adult, college, high school student, and military recruit 
samples. Convergent validity for the trait-version of the STAI has been demonstrated in 
significant correlations with other trait measures of anxiety for both Form Y and Form X 
(the prior STAI form) in normal populations (e.g., Creamer, Foran, & Bell, 1995; 
Spielberger et al., 1983). The total scores on each scale of this measure were used as 
independent variables in the study, indicating the participant's general level of anxiety. 
Self-Rating Anxiety Scale. The Self-Rating Anxiety Scale (SAS; Zung, 1971; 
Appendix E) is a rating instrument developed for the measurement of the most commonly 
agreed upon symptoms of anxiety. The instrument primarily measures somatic symptoms 
associated with anxiety (Olatunji, Deacon, Abramowitz, & Tolin, 2006). The SAS is the 
self-report component of a two-part instrument: the first part of the instrument, the 
Anxiety Status Inventory (ASI) is designed as an instrument to facilitate interview rating 
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of the examinee, whereas the SAS is a self-report instrument. The SAS consists of 20 
items using a four-point Likert-type scale on which each participant is expected to rate 
how much each of the items have applied to him/ herself within the last week. The 
participant responds with a "1" if the item has applied to him/ herself "none or a little of 
the time," "2" if it applied "some of the time," a "3" if it applied a "good part of the 
time," and a "4" if the item has applied to him/ herself "most or all of the time." Sample 
items from the SAS include "I feel more anxious and nervous than usual" and "I can 
breathe in and out easily." A total score is obtained by reverse scoring the items stated in 
an anxiety absent manner and then summing the 20 items of the SAS (Zung, 1971). 
Scores can range from 20 to 80, with a higher score indicating higher l evels of anxiety. 
The psychometric properties of the SAS appear to be solid. Zung (1971) reported an odd-
even split-half reliability of .71 and an internal consistency of .85. Additionally Jegede 
(1977) reported that the measure has demonstrated adequate internal consistency and test-
retest reliability. In correlational analysis between the SAS and other measures of 
anxiety, evidence of convergent validity was found, although evidence for discriminant 
validity is limited (Olatunji et al., 2006). The total score from this measure was used as 
an independent variable in the study, indicating the participant's general level of anxiety. 
Medical Anxiety Scale. The Medical Anxiety Scale (MAS; Pegg & Gardner, 
2006) is a measurement currently in development. That aims at being a comprehensive 
measure of the full spectrum of medical anxieties. The MAS includes facets already 
assessed by measures such as the Medical Fear Survey and Medical Avoidance Survey 
(Kleinknecht, Thorndike, & Walls, 1996), and the General Medical Anxiety Index (Van 
Balen & Verdurmen, 1999). Furthermore, the MAS includes items assessing for both 
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anxiety related to delay in seeking medical care and medical attention, as well as anxiety 
related avoidance of medical care and treatment. For the present study, the following 
specific subscales were culled from the MAS to assess anxiety in contexts potentially 
related to HIV testing or the treatment of AIDS: Blood/Injection/Injury Anxiety (See 
Appendix F); Germs Anxiety (See Appendix G); Hospital and X-Ray Anxiety (See 
Appendix H); and, Medications and Pharmacist-Related Anxiety (See Appendix I). 
Internal consistencies of the subscales employed in the present study, assessed during the 
development of the measure, vary between .85 (for the Germs Anxiety and Hospital and 
X-Ray anxiety subscales) and .92 (for the Blood/Injection/Injury subscale). The 
participant is presented with various statements relating to attitudes toward healthcare 
personnel and medical situations. The participant is expected to use the six-point Likert 
type scale to indicate the extent to which he or she agrees or disagrees with each 
statement. The six points of the scale are as follows: "1" is "Strongly Disagree"; "2" is 
"Somewhat Disagree"; "3" indicates "Slight Disagreement" with the statement; "4" is 
"Slightly Agree"; "5" is "Somewhat Agree"; or, "6" is "Strongly Agree". A total score is 
obtained by first reverse scoring those items that are stated in an anxiety absent manner, 
and then summing all the items of each subscale. The total scores from these subscales 
were used as independent variables in the study, indicating the participant's levels of 
Blood/Injection/Injury, Germs, Hospital and X-Ray, and Medications and Pharmacist 
Anxiety. 
Death Anxiety Scale. The Death Anxiety Scale (DAS; Templer, 1970; Appendix 
J) is one of the few measures of death anxiety. The DAS consists of 15 true-or-false 
statements (e.g. "I am very much afraid to die," "The thought of death seldom enters my 
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mind," and "It doesn't make me nervous when people talk about death"). A recently 
extended version includes the original 15 items as well as an additional 36 new items 
(Templer et al., 2006). Although the internal consistency for the extended scale is 
superior to the original version of the measure, Templer et al. (2006) states that 
researchers should consider both the participant's time and the purposes for which the 
measure is being used when deciding which version of the scale to adopt. The scale is 
scored by summing the anxious positive responses. Scores can range from 15 to 30, with 
a higher score indicating higher levels of death anxiety. Among the advantages of using 
the DAS as a measure of death anxiety are its brevity and ease of scoring, as well as its 
prior use in hundreds of studies (Templer et al., 2006). The instrument has also been 
formatted into a Likert format and has been used as such in other studies (Safren, 
Gershuny & Hendriksen, 2003; McMordie, 1979). Additionally, the scale has been 
translated into various different languages including Afrikaans, Arabic, Chinese, Dutch, 
French, German, Hindi, Italian, Japanese, Korean, Portuguese, Russian, Spanish, and 
Swedish (Templer et al., 2006). Stevens, Cooper and Thomas (1980) established age 
norms for the true-false format of the DAS. Psychometric properties for the DAS were 
found to be good with a test-retest reliability of .83 and a Kuder-Richardson internal 
consistency coefficient of .76 (Templer, 1970). In addition, Handal (1975) validated the 
DAS as an acceptable measure of the defense mechanism of repression. The total score 
from this measure was used as an independent variable in the study, indicating the 
participant's level of Death anxiety. 
Multidimensional AIDS Anxiety Questionnaire. An exhaustive review of the 
literature yielded only one measurement for the assessment of AIDS-specific anxiety. 
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Snell and Finney (1996) developed the Multidimensional AIDS Anxiety Questionnaire 
(MAAQ; 1996; Appendix K) consisting of 50 Likert-type scale questions assessing 
several areas of anxiety related to AIDS. These areas are: physiological arousal (as 
reflected by the item: "When I think about AIDS, I feel tense"), fear of AIDS (as 
reflected by the item: "I'm afraid of getting AIDS"), sexual inhibition (as reflected by the 
item: "AIDS makes me feel jittery about having sex with someone."), cognitive worry (as 
reflected by the item: "thinking about AIDS makes me feel anxious."), discussion 
inhibition (as reflected by the item: "I sometimes find it hard to discuss issues dealing 
with AIDS.") and anxiety about AIDS (as reflected by the item: "I 'm concerned that I 
might be carrying the AIDS virus."). Each participant is expected to rate his or her 
response to these statements on a five-point Likert-type scale. Participants indicate a 1 if 
the response is 'Not at all characteristic of me;' a 2 for 'Slightly characteristic of me;' a 3 
for 'Somewhat characteristic of me;' a 4 for 'Moderately characteristic of me;' and a 5 if 
the statement is 'Very characteristic of me.' The MAAQ is scored by reverse scoring the 
items that are anxiety absent after which the participant's responses are summed to yield 
a total score. The MAAQ shows high internal consistency (alphas of these various areas 
ranging between .85 and .94) (Snell & Finney, 1996). Scores can range from 50 to 250, 
with a higher score indicating higher levels of AIDS-specific anxiety. The total score 
from this measure was used as an independent variable in the study, indicating the 
participant's level of AIDS-specific anxiety. 
HIV Risk Assessment. In order to obtain a level of each participant's current HIV 
risk exposure, questions adopted from the CDC's published guidelines for HIV 
counseling, testing, and referral (CDC, 2001, Appendix L) were used. Participants can 
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complete this screening instrument either during a face-to-face interview, through a 
computer assisted interview, or by self report; however insufficient data exist to support 
the efficacy of any one of these approaches over any of the others (CDC, 2001). The 
assessment includes 6 true-false statements that assesses the individual's potential 
exposure to HIV due to behavioral risk (e.g. "Since your last HIV test [if ever], have you 
injected drugs and shared equipment [e.g., needles, syringe, cotton water] with others?") 
as well as assessing some clinical signs (e.g. Since your last HIV test [if ever], have you 
had a fever or illness of unknown cause?"). If a participant responds true to 1 or more of 
these 6 statements, he/she should be considered at an increased risk for HIV exposure. 
For the purpose of this study, each participant's responses will be summed to yield a total 
score indicating the participant's overall HIV risk. Scores can range from 0 to 6, with a 
higher score indicating higher levels of HIV risk. The total score from this measure was 
used in the study to control for the impact of current HIV risk on the dependent variables. 
HIV Knowledge Questionnaire. As noted above, several studies have indicated 
that knowledge about HIV/AIDS appears to be a determinant of behavior change (Carey 
& Schroder, 2002; Chliaoutakis & Trakas, 1996; Waldner et al., 1999). Participant's level 
of HIV/AIDS knowledge was assessed by completing the HIV Knowledge 
Questionnaire, 18 item version (HIV-KQ-18; Carey & Schroder, 2002; Appendix M). 
The HIV-KQ-18, is a shortened version of the original HIV Knowledge Questionnaire 
(HIV-K-Q), which consisted of 45 items (Carey, Morrison-Beedy, & Johnson, 1997). The 
HIV-KQ-18 consists of items aimed at measuring an individual's self-reported HIV-
related knowledge. The participant is required to respond to fact-based questions about 
HIV by indicating whether the presented statement is 'True' or 'False.' The measure is 
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scored by summing the number of correct responses. Scores can range from 0 to 18, with 
a higher score indicating better knowledge of HIV/AIDS. The HIV-KQ-18 demonstrated 
good internal consistency (alphas ranging between .79 and .89) as well as good test-retest 
reliability (ranging between .76 and .94) and correlational analysis indicated strong 
associations with other measures such as the HIV-K-Q (Carey & Schroder, 2002). The 
total score from this measure was used in the study to control for the impact of HIV 
knowledge on the dependent variables. 
Procedure 
Approval for this study was obtained from the Western Kentucky University's 
Human Subjects Review Board (Appendix N). Upon approval, a research assistant 
solicited participants in their various classes. Participants first signed an Informed 
Consent form (Appendix O). All participants were then assessed on a general level of 
anxiety by utilizing the STAI and the SAS. Participants were then required to complete a 
section querying personal demographics, HIV-related demographics, and relationship 
history. Additionally, participants completed the HIV-KQ-18 and an assessment of their 
current HIV risk. Participants then completed the measures that assessed specific or 
"narrowband" areas of anxiety: the MAAQ; the subscales of the MAS; and, the DAS. 
To address concerns about position effect in the administration of the 
assessments, two versions of the questionnaire packets used in the research were 
developed. The measures of specific anxiety were randomly assigned to one of two test 
versions. Each participant was then randomly assigned to either of the two test versions. 
This allowed the researchers to counterbalance partially the data collected. 
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Participants were required to complete the questionnaires online on a restricted-
to-user university study board. The participants were required to have a password to login 
to the University study board. The password was specific to a given participant and 
provided by the study board administrator. Moreover, after logging into the study board 
site, the participant must then opt to take the study and will not be able to access the 
study without specifically signing up for it through the study board. No access to the 
instruments being used in the study was permitted prior to the participant's consenting to 
participate in the study, nor were the instruments available to the participants after 
completion of the questionnaire. 
After the participants completed the bulk of the questionnaires comprising the 
research packet, a modified form of the state-version of the STAI was administered to 
determine if taking the survey itself caused any transient changes in level of anxiety. The 
instructions for the modified state-based anxiety inventory was framed so as to gauge the 
sensations of anxiety or anxiety related affect experienced by the participants during the 
administration of the research packet. At the conclusion of the research, a debriefing form 
(Appendix P) was presented that provided the participants with a list of resources 
available to them should they want to determine their HIV status. Contact information for 
mental health services was also provided for the unlikely contingency that any participant 
experienced distress as a consequence of his or her participation in the research. A list of 
websites that present information about HIV/AIDS, such as the Center for Disease 
Control's AIDS Awareness website, was also provided; notably, the CDC's website also 
provides a list of free and anonymous HIV testing sites. The entire procedure took 60-90 
minutes. 
Results 
Counterbalancing. The possibility of position effect was statistically managed via 
counterbalancing. T-tests were conducted to determine if any significant difference was 
obtained between the two different test versions. Independent samples t-tests were run 
between the participant's responses on the STAI, SAS, MAAQ, MAS subscales, and the 
DAS. The results of all of the performed t-test were non-significant suggesting no support 
for a hypothetical position effect. 
Missing Data. Missing data was replaced by performing an item-level mean 
imputation of the missing variables. This procedure was used only to address missing 
data on the measures of anxiety, i.e. on the STAI, SAS, MAAQ, MAS subscales, and the 
DAS. On the State version of the STAI, 18 (5.3%) participants failed to answer at least 1 
but no more than 3 items, resulting in missing data that was replaced through imputation. 
On the Trait version of the STAI, 28 (8.2%) of the participants failed to answer at least 1 
but no more than 3 items. On the SAS, 12 (3.5%) of the participants neglected to answer 
the measure completely with the resultant use of mean imputation. On the MAAQ, item-
level mean imputation was needed for 47 (13.7%) of the participants, who missed at least 
1 but no more than 4 of the items. The frequency of this procedure on the different 
subscales of medical anxiety were as follows: 10 participants (2.9%) on the 
Blood/Injection/Injury subscale of the MAS; 11 participants (3.2%) on the Hospital and 
X-Ray subscale of the MAS; 4 participants (1.2%) on the Germs subscale of the MAS; 
and 7 participants (2%) on the Medications and Pharmacist subscale of the MAS missed 
items and required mean imputation. On the DAS, item-level mean imputation was 
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needed for 8 (2.3%) of the participants who missed at least 1 but no more than 2 of the 
items. 
After imputing the means of the items, item scores for each measure were then 
summed, according to the requirements of each measure, to yield the relevant subscale 
and total scores used in further data analysis. 
Internal Consistency of Measures. In order to assess the reliability of the 
measures used in the study, the internal consistency of each of the measures used as 
independent variables during the multiple regression analyses was obtained. The 
reliability of the measures for General (or broad-based) anxiety were as follows: State 
anxiety (Cronbach's Alpha = .93), Trait anxiety (Cronbach's Alpha = .93), SAS 
(Cronbach's Alpha = .83). Reliability scores for the measures of specific anxiety were as 
follows: MAAQ (Cronbach's Alpha = .96) and DAS (Cronbach's Alpha = .79). The 
reliability scores for the different measures of subtypes of medical anxiety were as 
follows: the Blood/Injection/Injury subscale of the Medical Anxieties Scale (MAS) 
(Cronbach's Alpha = .83), the Hospital and X-Ray subscale of the MAS (Cronbach's 
Alpha =.86), the Germs subscale of the MAS (Cronbach's Alpha =.89), and the 
Medications and Pharmacist subscale of the MAS (Cronbach's Alpha =.85). 
Descriptive Statistics. The mean and standard deviation of the participants' total 
scores on each of the measures of anxiety are provided in Table 4, as well as the range on 
each of these instruments. Additionally, the participants are grouped according to their 
responses on the demographic questions. The mean and standard deviation on each of the 
measures of anxiety are provided according to the participant's gender (Male or Female) 
in Table 5, ethnicity (Caucasian or Non-Caucasian) in Table 6, prior HIV testing history 
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in Table 7, past sexual history in Table 8, and relationship status (Single or "In a 
relationship") in Table 9. 
Table 4 
Descriptive Statistics of Participants' raw scores across the measures of anxiety. 
Measure of Anxiety Mean Standard Instrument 
Deviation Range 
State Anxiety 38.15 11.15 2 0 - 8 0 
Trait Anxiety 39.44 11.25 2 0 - 8 0 
Self-rating Anxiety Scale 33.73 7.81 2 0 - 8 0 
Multidimensional AIDS Anxiety 
Questionnaire 93.34 31.65 50 - 250 
Medical Anxiety 
Blood/Injection/Injury 20.88 9.66 7 - 4 2 
Germs 25.42 10.26 1 0 - 6 0 
Hospital and X-Ray 35.37 12.31 1 1 - 6 6 
Medications and Pharmacist 19.98 9.27 1 0 - 6 0 
Death Anxiety 22.64 3.53 1 5 - 3 0 
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Table 11 
Descriptive Statistics of Male and Female raw scores across the measures of anxiety. 
Male Female 
Mean Standard Mean Standard 
Measure of Anxiety Deviation Deviation 
State Anxiety 37.57 11.28 38.41 11.02 
Trait Anxiety 38.47 11.57 39.93 10.99 
Self-rating Anxiety Scale 32.17 7.77 34.64 7.65 
Multidimensional AIDS Anxiety 
Questionnaire 89.86 30.49 95.70 32.81 
Medical Anxiety 
Blood/Injection/Injury 18.69 8.92 22.26 9.81 
Germs 22.14 9.45 27.38 10.21 
Hospital and X-Ray 33.05 11.03 36.63 12.85 
Medications and Pharmacist 19.09 8.40 20.47 9.69 
Death Anxiety 23.72 3.30 21.97 3.52 
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Table 11 
Descriptive Statistics of Caucasian and Non-Caucasian raw scores across the measures 
of anxiety. 
Caucasian Non-Caucasian 
Measure of Anxiety 
Mean Standard 
Deviation 
Mean Standard 
Deviation 
State Anxiety 37.96 11.09 38.67 11.02 
Trait Anxiety 39.13 11.04 41.04 12.21 
Self-rating Anxiety Scale 33.65 7.88 33.99 6.89 
Multidimensional AIDS Anxiety 
Questionnaire 91.33 30.78 106.92 35.53 
Medical Anxiety 
Blood/Injection/Injury 20.52 9.62 22.73 9.39 
Germs 25.24 10.19 26.36 10.40 
Hospital and X-Ray 35.10 12.05 36.05 13.36 
Medications and Pharmacist 19.62 9.17 21.82 9.43 
Death Anxiety 22.65 3.53 22.37 3.69 
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Table 11 
Descriptive Statistics of Participant's (with history ofprior or no prior HIV testing) raw 
scores across the measures of anxiety. 
Prior HIV Test No Prior HIV Test 
Mean Standard Mean Standard 
Measure of Anxiety Deviation Deviation 
State Anxiety 37.56 11.70 38.17 10.94 
Trait Anxiety 39.21 12.00 39.21 11.06 
Self-rating Anxiety Scale 35.85 8.81 33.24 7.43 
Multidimensional AIDS Anxiety 
Questionnaire 92.94 31.05 93.70 32.15 
Medical Anxiety 
Blood/Injection/Injury 20.19 10.25 20.97 9.47 
Germs 26.31 10.92 25.20 10.06 
Hospital and X-Ray 34.24 13.37 35.45 11.99 
Medications and Pharmacist 20.11 9.54 19.90 9.17 
Death Anxiety 22.83 3.56 22.56 3.56 
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Table 11 
Descriptive Statistics of Participant's (with histoiy of sexually active or no sexually 
active historyj raw scores across the measures of anxiety. 
Sexually Active Past No Sexually Active Past 
Mean Standard Mean Standard 
Measure of Anxiety Deviation Deviation 
State Anxiety 38.42 11.04 37.20 11.17 
Trait Anxiety 39.96 11.14 38.04 11.40 
Self-rating Anxiety Scale 34.30 8.06 32.08 6.60 
Multidimensional AIDS Anxiety 
Questionnaire 94.60 32.84 91.19 29.30 
Medical Anxiety 
Blood/Injection/Injury 20.52 9.73 21.71 9.33 
Germs 25.36 10.40 25.57 9.76 
Hospital and X-Ray 35.25 12.23 35.40 12.43 
Medications and Pharmacist 19.90 9.30 20.12 9.13 
Death Anxiety 22.38 3.51 23.18 3.56 
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Table 11 
Descriptive Statistics of Single Participant's or Participants in a relationship's raw 
scores across the measures of anxiety. 
Single In a Relationship 
Mean Standard Mean Standard 
Measure of Anxiety Deviation Deviation 
State Anxiety 40.14 10.55 36.73 11.23 
Trait Anxiety 41.34 11.68 38.15 10.77 
Self-rating Anxiety Scale 34.00 7.73 33.51 7.78 
Multidimensional AIDS Anxiety 
Questionnaire 99.18 32.83 89.45 30.09 
Medical Anxiety 
Blood/Injection/Injury 20.69 9.74 20.93 9.56 
Germs 24.36 10.34 26.11 10.09 
Hospital and X-Ray 35.05 12.15 35.45 12.28 
Medications and Pharmacist 20.04 8.61 19.88 9.64 
Death Anxiety 22.64 3.53 22.60 3.58 
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Furthermore, Table 10 presents the mean and standard deviation of each 
participant's response to the likelihood of being tested for HIV and the likelihood of 
returning for the results of HIV testing. Additionally, the mean and standard deviation of 
participant's responses to the likelihood of being tested for HIV and the likelihood of 
returning for the results of HIV testing are provided according to the participant's gender 
(Male or Female), ethnicity (Caucasian or Non-Caucasian), prior HIV testing history, 
past sexual history, and relationship status (Single or "In a relationship") in Table 11. 
Table 10 
Descriptive Statistics of Participants across the likelihood of being tested for HIV and the 
likelihood of returning for the results of HIV testing. 
Mean Standard Range 
Deviation 
Likelihood of Being 
Tested for HIV Status 5.63 3.39 1 - 10 
Likelihood of Returning for 
the Results of HIV testing 6.58 3.58 1 - 10 
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Table 11 
Descriptive Statistics of Respondents across the likelihood of being tested for HIV and 
the likelihood of returning for the results of HIV testing grouped by demographics 
Demograpics 
Likelihood of Being 
Tested for HIV 
Likelihood of Returning 
for results of HIV test 
Mean Standard 
Deviation 
Mean Standard 
Deviation 
Gender 
Male 5.19 
Female 5.90 
Ethnicity 
Caucasian 5.49 
Non-Caucasian 6.53 
HIV testing history 
Prior HIV Testing 7.90 
No Prior HIV Testing 5.14 
Sexual History 
Sexually Active Past 6.13 
No Sexually Active Past 4.26 
Relationship Status 
Single 5.30 
In a Relationship 5.74 
3.49 
3.32 
3.41 
3.25 
2.94 
3.29 
3.26 
3.42 
3.46 
3.43 
6.37 
6.66 
6.41 
7.40 
7.90 
6.25 
6.81 
5.81 
6.35 
6.72 
3.57 
3.51 
3.54 
3.37 
3.03 
3.57 
3.42 
3.75 
3.53 
3.58 
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Likelihood of Being Tested for HIV. Hypotheses designed to answer research 
questions related to the Likelihood of Being Tested for HIV were tested using a stepwise 
regression analyses to determine which of the independent variables included in the data 
analysis were the strongest predictor(s) of the likelihood of being tested for HIV. 
Independent variables included State Anxiety (Total score from the State version of the 
STAI), Trait Anxiety (Total score from the Trait version of the STAI), General Anxiety 
(Total score from the SAS), AIDS-Specific Anxiety (Total score from the MAAQ), 
Blood/Injection/Injury Anxiety (Total score from the MAS, Blood/Injection/Injury 
subscale), Germs Anxiety (Total score from the MAS, Germs subscale), Hospital and X-
Ray Anxiety (Total score from the MAS, hospital and X-Ray subscale), Medications and 
Pharmacist Anxiety (Total score from the MAS, Medications and Pharmacist subscale), 
and Death anxiety (Total score from the DAS). Stepwise regression revealed that a single 
variable, AIDS-Specific Anxiety, was the strongest predictor of the likelihood of being 
tested for HIV {R = .139, R2adj = .016, F( 1, 340) = 6.68, p = <.05). Overall, the model 
retained after regression analysis accounted for only 13% of variance in the likelihood of 
getting tested for HIV. See Table 12 for a summary of the overall model. Table 13 
displays the bivariate and partial correlation coefficients for the final model. 
Table 12 
Model Summary for Variable(s) Predicting Likelihood of Being Tested for HIV 
Step R R2 R2adj A R2 Fchg p d f i d f 2 
AIDS-Specific Anxiety .139 .019 .016 .019 6.68 <.05 1 340 
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Table 11 
Coefficients for Final Model Predicting Likelihood of Being Tested for HIV 
B P t Bivariate r Partial r 
AIDS-Specific Anxiety .015 .006 2.58* .010 .004 
Note. *p < .05. 
Likelihood of Returning for HIV Test Results. Hypotheses developed to answer 
research questions related to the Likelihood of Returning for HIV Test Results were 
tested using a stepwise regression analysis to determine which of the independent 
variables were the strongest predictor(s) of the Likelihood of Returning for HIV Test 
Results. The independent variables included in the analysis were State anxiety (Total 
score from the State version of the STAI), Trait anxiety (Total score from the Trait 
version of the STAI), General anxiety (Total score from the SAS), AIDS-Specific anxiety 
(Total score from the MAAQ), Blood/Injection/Injury anxiety (Total score from the 
MAS, Blood/Injection/Injury subscale), Germs anxiety (Total score from the MAS, 
Germs subscale), Hospital and X-Ray anxiety (Total score from the MAS, hospital and 
X-Ray subscale), Medications and Pharmacist anxiety (Total score from the MAS, 
Medications and Pharmacist subscale), and Death anxiety (Total score from the DAS). 
Stepwise regression revealed that a single variable, Hospital and X-Ray anxiety, was the 
•y 
strongest predictor of the Likelihood of Returning for HIV test Results (R = .121, R
 aeij = 
.012, F(l , 340) = 5.07,p = <.05). Overall, the variable retained after regression analysis 
accounted for only 12% of the variance of the model. See Table 14 for a summary of the 
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overall model. Table 15 displays the bivariate and partial correlation coefficients for the 
final model. 
Table 14 
Model Summary for Variable(s)Predicting Likelihood of Returning for HIV Test Results 
Step R R2 R2
 adj AR2 Fchg p d f , df2 
Hospital and X-Ray 
Anxiety .121 .015 .012 .015 5.07 < 0 5 1 340 
Table 15 
Coefficients for Final Model Predicting Likelihood of Returning for HIV Test Results 
B P t Bivariate r Partial r 
Hospital and X-Ray 
Anxiety .035 .016 2.25* .025 .004 
Note. *p < .05. 
Exploratory Analyses. Upon completion of the proposed study, several factors 
influenced the decision to do exploratory analyses. When considering that the expected 
results where not obtained and that unequivocal support for the proposed hypotheses was 
not provided, I deemed it necessary to re-review the data collected in an attempt to 
explore possible explanations as to the results. Considering the low amount of variance 
attributed to the various anxiety measures, I decided to explore the impact of other 
factors, specifically, the influence of the individual's demographics on the models. In 
order to control for the effects of subject related extraneous variables on the 
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aforementioned models, linear regression analyses were performed to determine to what 
extent the extraneous variables influenced the likelihood of being tested for HIV as well 
as the likelihood of returning for HIV test results. The participants responses to gender 
(Male or Female), ethnicity (Caucasian or Non-Caucasian), previous HIV testing history 
("Have taken a HIV test" or "Not taken a HIV test"), past sexual history ("Have been 
sexually active" or "Have never been sexually active"), and relationship status ("Single" 
or "In a relationship"), current HIV risk (Total score from the HIV risk assessment), and 
HIV knowledge (Total score from HIV-KQ-18), were regressed onto each of the two 
dependent variables and unstandardized residual scores were calculated. The 
unstandardized residual score represents the variance in the dependent variable's score 
after the variance that can be explained by the extraneous variables have been removed. 
For this study i.e. it would mean that the unstandardized residual score for the likelihood 
of being tested for HIV as well as the likelihood to return for the results represent the 
likelihood that has been adjusted for the effect of the various demographics. The stepwise 
regression analyses to determine which of the independent variables were the strongest 
predictor(s) of the two dependent variables - that is, the likelihood of being tested for 
HIV and the likelihood of returning for HIV test results - were repeated using the 
unstandardized residual scores of each of these dependent variables. The stepwise 
regression analysis revealed that no model was retained for either of the dependent 
variables, i.e. none of the independent anxiety measures accounted for a significant 
amount of variance in the models. 
Furthermore, considering that there is such a scarcity in the literature with regards to 
the influence of anxiety on HIV testing behavior as well as HIV/AIDS anxiety in general, 
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I decided to explore this area even thought this is not what I originally set forth to 
accomplish. Considering the data collected I deemed that the most fruitful exploratory 
analyses would be to explore, albeit briefly, the impact of the various factors on AIDS-
Specific anxiety. This was accomplished by performing a stepwise regression analysis to 
explore the influence of the various anxieties on AIDS-Specific anxiety. The independent 
variables included: State anxiety (Total score from the State version of the STAI), Trait 
anxiety (Total score from the Trait version of the STAI), General anxiety (Total score 
from the SAS), Blood/Injection/Injury anxiety (Total score from the MAS, 
Blood/Injection/Injury subscale), Germs anxiety (Total score from the MAS, Germs 
subscale), Hospital and X-Ray anxiety (Total score from the MAS, hospital and X-Ray 
subscale), Medications and Pharmacist anxiety (Total score from the MAS, Medications 
and Pharmacist subscale), and Death anxiety (Total score from the DAS). The dependent 
variable was the participants reported AIDS-Specific anxiety (as indicated by the total 
score from the MAAQ). Results revealed an overall model of three predictors: Death 
anxiety (R = .57, R2adj = .255, F{ 1, 340) = 117.85,p = <.05); Germs anxiety (R = .56, 
R2adj = -315, F( 1, 339) = 30.82,p = <.05) and Trait anxiety (R = .57, R2adj = .327, F( 1, 
338) = 26.18,p = <.05). This model accounted for 33% of variance on AIDS-Specific 
anxiety. See Table 16 for a summary of the overall model. Table 17 displays the 
bivariate and partial correlation coefficients for the final model. 
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Table 11 
Model Summary for Variable(s) Predicting AIDS-Specific Anxiety 
Step R R2 R2ndj AR2 Fchg p d f , df2 
Death Anxiety .507 .257 .255 .257 117.85 <.05 1 340 
Germs Anxiety .565 .319 .315 .062 30.82 <.05 1 339 
Trait Anxiety .577 .333 .327 .014 6.97 <.05 1 338 
Table 17 
Coefficients for Final Model Predicting AIDS-Specific Anxiety 
B p t 
Death Anxiety -3.005 -.335 -6.365 
Germs Anxiety .824 .263 5.194 
Trait Anxiety .365 .128 2.641 
Discussion 
The purpose of this study was to determine the influence of anxiety - both general 
and specific types of anxiety - on prospective HIV testing behavior. The hypotheses 
under study focused on the extent to which General anxiety, AIDS-Specific anxiety, 
Blood/Injection/Injury anxiety, Germs anxiety, Hospital and X-Ray anxiety, Medications 
and Pharmacist anxiety, and Death anxiety, would influence disease-status testing-related 
variables: Likelihood of Being Tested for HIV and the Likelihood of Returning for the 
Results of HIV Testing. Hypotheses concerning the Likelihood of Being Tested for HIV 
stated that lower levels of likelihood to be tested for HIV would be associated with higher 
levels of General anxiety, AIDS-Specific anxiety, Blood/Injection/Injury anxiety, Germs 
anxiety, Hospital and X-Ray anxiety, Medications and Pharmacist anxiety as well as 
higher levels of Death anxiety. Hypotheses concerning the Likelihood of Returning for 
HIV Test Results stated that a higher likelihood of failure to return for HIV test results 
would be associated with higher levels of General anxiety, AIDS-Specific anxiety, 
Blood/Injection/Injury anxiety, Germs anxiety, Hospital and X-Ray anxiety, Medications 
and Pharmacist anxiety, and Death anxiety. 
The current study did not provide unequivocal support for the hypotheses. 
Although, a higher degree of AIDS-Specific anxiety influenced the likelihood of 
receiving a HIV test and a higher level of both Hospital and X-Ray anxiety influenced the 
likelihood of failing to return to receive the results of a HIV test, the variance attributed 
to each of these was of a low order. Once the researchers controlled for such relevant 
demographic variables as gender, ethnicity, previous HIV testing history, past sexual 
history, relationship status, current HIV risk, and HIV knowledge, the variance accounted 
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for in the two regression equations by AIDS-Specific Anxiety and Hospital and X-Ray 
Anxiety, respectively, was no longer significant and none of the variables in the study 
were retained in a model. These results could potentially be due to some identified 
limitations of the present study. The findings of the research were no doubt influenced by 
the fact that the vast majority of the college-aged participants in the study did not report a 
significantly high incidence of past HIV testing behavior or current HIV risk exposure. It 
is arguable that participants with a greater risk exposure to HIV may exhibit different 
HIV testing behavior, for example being more or less likely to obtain a HIV test. 
Additionally, participants who have a prior history of HIV testing may be more likely to 
seek out future testing considering that they have already been through the experience. 
Considering the population of participants for this study, it is arguable that results were 
not significant since these participants have no prior motivation or experience that guided 
their HIV testing behavior. Moreover, the dependent variables chosen may have been 
sub-optimal. Participants were expected to rate their HIV testing behavior based on a 
hypothetical vignette, and although the researchers made an effort to present a plausible 
scenario, the results very likely would have been significantly different if the participants 
were assessed in vivo while actually submitting to an HIV test. 
When considering the results it is also important to note the influence of (at least 
within the context of the present study) extraneous variables. Past research has suggested 
that specific individual characteristics, such as gender, ethnicity, and knowing someone 
who is HIV positive, influence HIV testing behavior (Camlin & Chimbwete, 2003; 
Hightow et al, 2003; Keenan & Keenan, 2001; Macintyre et al., 2001). The impact of 
demographic and HIV-status related variables on the present study provides 
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substantiation for these findings. Furthermore, the impact of factors like gender, 
ethnicity, and prior HIV-testing history raises the possibility that HIV testing behavior 
may be largely due to the specific characteristics and experiences of the individual rather 
than a more etic or universal experience of anxiety. 
It is noteworthy that the results of our exploratory analyses indicated that Death 
anxiety, Germs anxiety and Trait anxiety, all added significantly to the prediction of 
AIDS-Specific anxiety in a stepwise regression. Several studies have made mention of 
the fear associated with HIV/ AIDS (Kaijaleena & Aavarinne, 1999; Waldner et al, 1999; 
Worthington & Myers, 2003). Arguably, HIV testing behavior may be influenced by 
AIDS-Specific anxiety, which, at least according to the results of the present study, may 
be influenced by other specific types of anxiety. Ultimately receiving a positive HIV test 
result can be interpreted by the individual who receives the results as a death sentence, 
since there is currently no cure for HIV/ AIDS. When looking at HIV from this 
perspective, it becomes apparent why Death anxiety may have such a significant impact 
on AIDS-Specific anxiety. 
Considering the dearth of past research as concerns the influence of anxiety on 
HIV testing behavior, the results of this study, although limited, do provide some insight 
into the role anxiety may play. The strength of the study therefore lies within its attempt 
to contribute to the field as it yielded some information about the role of anxiety on HIV 
testing behavior. As noted by Janssen et al. (2001) one approach to reducing HIV 
incidence in the USA would be to increase the number of HIV-infected persons who are 
aware of their serostatus. Possibly this study could springboard future research in the area 
of HIV testing behavior. It is arguable that a greater understanding of factors impacting 
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an individual's HIV testing behavior might ultimately lead to an improved testing 
experience, which could decrease the vast number of individuals without knowledge of 
their HIV status and ultimately may contribute to the decrease of HIV incidence. 
Limitations and Future Research. As noted above, there are some possible 
limitations to the present study. The population for this study consisted entirely of 
college-aged individuals. Additionally, the participants were all students drawn from a 
university in a relatively rural part of the southern USA. Few of these students reported a 
past history of prior HIV testing, although almost three quarters of the sample reported a 
past history of being sexually active. The results obtained may have been different if the 
population used were either individuals who are more likely to be tested for HIV or 
individuals at an elevated risk of HIV infection. A similar study may be fruitfully 
repeated using a more demographically diverse population (for example a population 
with older participants, more ethnically diverse participants and/ or participants with 
different education level). Furthermore, it may be beneficial to repeat the study in a 
population in which the participants were more likely to have been exposed to 
seropositive individuals; resulting in either a higher rate of prior testing for HIV status 
and/or a more likely, higher HIV risk. 
Furthermore, the questions used to measure the dependent variables were derived 
from a hypothetical vignette asking the participant to rate the likelihood of taking a 
hypothetical HIV test. It is possible that the vignette failed to evoke a vividly imaginable 
experience of being tested for HIV and thus did not engender the full range of feelings of 
anxiety that would accompany the actual HIV testing experience. Ideally, future studies 
may want to aim at measuring a participant's levels of anxiety, in vivo, i.e. having a 
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participant complete the measure of anxiety immediately prior to receiving an actual HIV 
test. Additionally, the exclusive reliance on self-report measures may have limited the 
results. It is not unlikely that some of the participants may have randomly answered the 
questions or may have done so in a socially desirable fashion, the latter being especially 
problematic, considering that many of the questions dealt with sexual practices. 
Another limitation to the present study is evident in the data analytic strategies 
employed to investigate the influence of anxiety on HIV testing behavior. Since the 
emphasis of the research was on the relationship between anxiety and HIV testing 
behavior, regression analytic strategies were utilized to explore the influence of various 
types of anxiety on HIV-testing related attitudes. However, when considering that 
extraneous variables appeared to impact the interpretation of the regression models, 
future research would benefit from a more exhaustive focus on the role of factors such as 
age, gender, past HIV testing history, past sexual history, relationship status, and HIV 
knowledge, on HIV testing behavior. 
Conclusion. Despite the distinct possibility that anxiety plays a role in decisions 
concerning HIV testing - for example, as a causal factor influencing failure to return for 
the results of HIV testing - an extensive literature review yielded no study that 
specifically examined the association between anxiety and HIV testing behavior. The 
current study attempted to bridge this gap, and, although it did not yield the anticipated 
results, the findings contributed to research concerning the factors that potentially 
influence HIV testing behavior. Although limited, the results suggest the influence of 
anxiety on HIV testing behavior. However, more noteworthy, the impact of personal 
variables, such as the individual's demographics, prior HIV testing and HIV exposure 
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was seen. This influence of the individual's demographics not only provides 
substantiation for prior findings which explored the impact of such factors on HIV testing 
behavior, but also raises the possibility that HIV testing behavior may be largely due to 
the specific characteristics and experiences of the individual rather than a more etic or 
universal experience of anxiety. The findings presented here may provide future 
researchers with a starting point for further empirical endeavors. Considering the 
limitations to this study and applying the suggestions derived from frankly addressing 
these limitations, future research may indeed reveal a significant impact of anxiety on 
HIV testing behavior. 
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Appendix A 
Dependent Variables Questions 
81 
The following is a completely hypothetical (i.e. not true) situation. 
We would like for you to vividly imagine that you have the opportunity TODAY to take 
a HIV test. The test will be offered free of charge; you are assured of its anonymity, 
accuracy and you can choose the HIV testing process that you prefer. In other words, you 
will be given the opportunity to pick whether you want to give a blood, urine or oral 
specimen; you can pick if you want to use a rapid test (results available in less than 20 
minutes) or original testing (results will be available in about 2 weeks); you can choose 
how you would like to receive the results (i.e. whether you will be notified by mail, have 
to return to the testing facility to get the results, be contacted by the facility to set-up a 
scheduled appointment to receive results, etc.) 
1. On a scale of 1 to 10 with "1" being 'Not likely at all' and "10" being 'Extremely 
likely', please indicate how likely you would be to have HIV testing done today under the 
circumstances noted above. 
1 2 3 4 5 6 7 8 9 10 
Not likely Somewhat Extremely 
at all likely likely 
2. On a scale of 1 to 10 with "1" being 'Not likely at all' and "10" being 'Extremely 
likely', please indicate how likely you would be to return to receive the results of your 
HIV testing. 
1 2 3 4 5 6 7 8 9 10 
Not likely 
at all 
Somewhat 
likely 
Extremely 
likely 
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Appendix B 
Demographics 
83 
1. Age: 
2. Please circle your gender 
a. Male 
b. Female 
3. Please indicate your ethnicity: 
a. African-American 
b. Asian 
c. Caucasian 
d. Hispanic /Latino 
e. Middle Eastern 
f. Native American 
g. Pacific Islander 
4. What is your current school level? 
a. First year 
b. Second year 
c. Third year 
d. Fourth Year 
e. Graduate Student 
5. What is the highest level of education your father completed? 
a. Some High School or less 
b. High School 
c. Some College 
d. College degree 
e. Graduate degree 
f. Don't Know 
What is the highest level of education your mother completed? 
a. Some High School or less 
b. High School 
c. Some Collage 
d. College degree 
e. Graduate degree 
f. Don't Know 
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Appendix C 
Questions about Relationship history 
86 
1. What type of relationship are you currently in? 
a. Single 
b. Seeing someone 
c. Steady relationship 
d. Engaged 
e. Married 
2. How would you describe your sexual orientation? 
a. Heterosexual 
b. Homosexual 
c. Bisexual 
3. Have you ever been sexually active? 
a. Yes 
b. No 
4. If Yes to question 4, 
4.1 When did you first become sexually active? Age 
4.2 How many sexual partners have you had (including your first and current 
partner)? 
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Appendix D 
HIV/AIDS and HIV testing related demographics 
88 
1. Do you personally (i.e. a close friend, relative, etc.) know someone who is currently 
HIV Positive or has AIDS? 
a. Yes 
b. No 
2. Do you know anyone who is currently HIV Positive or has AIDS? 
a. Yes 
b. No 
3. Have you ever know someone personally (i.e. a close friend, relative, etc.) who has 
passed away due to being infected with HIV/ AIDS? 
a. Yes 
b. No 
4. Have you ever know of anyone who has passed away due to being infected with HIV/ 
AIDS? 
a. Yes 
b. No 
5. Do you know your own personal HIV status? 
a. Yes 
b. No 
6. Have you ever taken a HIV / AIDS test? 
a. Yes 
b. No 
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Appendix E 
Self-rating Anxiety Scale 
90 
Please carefully read each item in the list. Based on how you felt in the PAST WEEK, 
INCLUDING TODAY, indicate how much you have experienced each of the following 
by placing an X in the corresponding space in the column next to each item. 
NONE or A 
LITTLE 
OF THE 
TIME 
SOME OF 
THE TIME 
GOOD PART OF 
THE TIME 
MOST or ALL 
OF THE 
TIME 
1. I feel more nervous and anxious than 
usual 
2 .1 feel afraid for no reason at all 
3.1 get upset easily or feel panicky 
4 .1 feel like I 'm falling apart and going 
to pieces 
5. I feel that everything is all right and 
nothing bad will happen 
6. My arms and legs shake and tremble 
7.1 am bothered by headaches, neck 
and back pains 
8.1 feel weak and get tired easily 
9.1 feel calm and can sit still easily 
10.1 can feel my heart beating fast 
11.1 am bothered by dizzy spells 
12.1 have fainting spells or feel like it 
13.1 can breathe in and out easily 
14.1 get feelings of numbness and 
tingling in my fingers, toes 
15. I am bothered by stomachaches or 
indigestion 
16.1 have to empty my bladder often 
17. My hands are usually dry and warm 
18. My face gets hot and blushes 
19.1 fall asleep easily and get a good 
night's rest 
20. I have nightmares 
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Appendix F 
Medical Anxiety Scale: Blood/Injection/Injury subscale 
92 
Presented below are a series of statements relating to your attitudes toward healthcare 
personnel and medical situations. Read each of the statements carefully. Beside each 
statement you will find a rating scale. This scale extends from "Strongly Disagree" to 
"Strongly Agree". The six points of the scale are as follows: "1" is Strongly Disagree; 
"2" is Somewhat Disagree; "3" indicates slight disagreement with the statement; "4" is 
Slightly Agree, "5" is Somewhat Agree, or, "6" is Strongly Agree. For each statement, 
check or fill in the circle that best indicates your attitude. Please answer all questions 
thoughtfully. 
1. Needles and injections terrify me. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
2. Having blood being drawn from my arm makes me woozy and/or nauseous. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
3. Needles and shots don't cause me any sense of alarm. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
4. I feel faint when I have blood drawn. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
5. The period of waiting for the results of medical tests is very anxiety provoking. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
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6. I don't mind having blood drawn. 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
7, I fear visits to the doctor because I know there may be a needle or a blood test 
involved. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
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Appendix G 
Medical Anxiety Scale: Germs subscale 
95 
Presented below are a series of statements relating to your attitudes toward healthcare 
personnel and medical situations. Read each of the statements carefully. Beside each 
statement you will find a rating scale. This scale extends from "Strongly Disagree" to 
"Strongly Agree". The six points of the scale are as follows: "1" is Strongly Disagrees 
"2" is Somewhat Disagree; "3" indicates slight disagreement with the statement; "4" is 
Slightly Agree, "5" is Somewhat Agree; or, "6" is Strongly Agree. For each statement, 
check or fill in the circle that best indicates your attitude. Please answer all questions 
thoughtfully. 
1. Doctor's waiting rooms are filled with germs from all the sick people who pass 
through them. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
2. I intentionally avoid being around sick people to keep from getting ill myself. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
3. When I hear about a serious infectious disease, I worry that I'll catch it. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
4. I'm made anxious by the fact that they may not sterilize the medical instruments at 
my doctor's office after every use. 
© © ® © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
5. I'm afraid that the instruments used in a doctor's office aren't disinfected after every 
examination. 
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© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
6. I'm disgusted by all the germs that are on the medical instruments in my doctor's 
examination room. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
7. I get frightened for my health when I hear news stories about major current health 
risks like the AIDS virus. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
8. Germs are transmitted between patients because doctors and nurses don't sterilize the 
medical instruments they use. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
9. Because they're filled with "sick" people, I'm afraid I'll catch something from sitting 
in a doctor's examination room. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
10. The thought of all the germs in a doctor's office make me nervous. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
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Appendix H 
Medical Anxiety Scale: Hospital & X-Ray subscale 
98 
Presented below are a series of statements relating to your attitudes toward healthcare 
personnel and medical situations. Read each of the statements carefully. Beside each 
statement you will find a rating scale. This scale extends from "Strongly Disagree" to 
"Strongly Agree". The six points of the scale are as follows: "1" is Strongly Disagree; 
"2" is Somewhat Disagree; "3" indicates slight disagreement with the statement; "4" is 
Slightly Agree] "5" is Somewhat Agree, or, "6" is Strongly Agree. For each statement, 
check or fill in the circle that best indicates your attitude. Please answer all questions 
thoughtfully. 
1. Everything about a hospital - the colors, the long corridors, the smells - makes me 
anxious. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
2. It scares me to be in a hospital that's filled with sick people and all those germs. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
3. The level of cleanliness in hospitals is generally very high. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
4. I get anxious even visiting a hospital. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
5. Hospitals are full of germs and bacteria, many of which can make you very ill. 
© © © © © © 
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Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
6. If I had a major surgery done, I'd be afraid they would leave something inside me, 
like a surgical tool or sponge. 
© © © .© © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
7. Hospitals make me anxious because when you're a patient you're really not in 
control of your life. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
8. Hospitals are associated with severe illness or death. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
9. The idea of being a patient in a hospital scares me because I probably wouldn't 
clearly understand a lot of what was going on with my treatment. 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
10. Hospitals may harm as many people as they cure. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
11. I have (or would have) no real problem being a hospital patient. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
12. I 'm frightened that X-Rays and the other ways they use to take images (like MRIs 
and CAT scans) might cause permanent physical damage. 
© © © © © © 
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Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
13. Whenever I get an X-Ray (or an MRI or CAT scan), I visualize them finding 
something disturbing like a tumor. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
14. If I had to get an MRI or CT scan - where I was put into an enclosed space to have a 
picture taken - I would very likely have an anxiety attack. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
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Appendix I 
Medical Anxiety Scale: Medications and Pharmacist subscale 
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Presented below are a series of statements relating to your attitudes toward healthcare 
personnel and medical situations. Read each of the statements carefully. Beside each 
statement you will find a rating scale. This scale extends from "Strongly Disagree" to 
"Strongly Agree". The six points of the scale are as follows: "1" is Strongly Disagree; 
"2" is Somewhat Disagree; "3" indicates slight disagreement with the statement; "4" is 
Slightly Agree; "5" is Somewhat Agree', or, "6" is Strongly Agree. For each statement, 
check or fill in the circle that best indicates your attitude. Please answer all questions 
thoughtfully. 
1. The act of taking medication generally doesn't cause me any anxiety. 
© © ® © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
2. I'm always afraid that either the doctor or the pharmacist has made a mistake of some 
kind when I have to take medication. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
3. I dread the idea of having to take any medication. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
4. I 'm afraid of taking vaccines because I may react badly to them. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
5. Taking any medication at all makes me anxious. 
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© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
6. I get nervous about all that could go wrong when I take any new medication. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
7. I generally experience no anxiety when I have to take medications. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
8. I'm afraid that the pharmacist will misread my doctor's handwriting on a 
prescription. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
9. I'm nervous that my pharmacist will fill my prescription incorrectly and harm me as a 
result. 
© „._.© © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
10. I feel safe taking the medications I've received from pharmacists. 
© © © © © © 
Strongly Somewhat Slightly Slightly Somewhat Strongly 
Disagree Disagree Disagree Agree Agree Agree 
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Appendix J 
Death Anxiety Scale 
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Please circle true or false 
1. I am very much afraid to die. True False 
2. The thought of death seldom enters my mind. True False 
3. It doesn't make me nervous when people talk about death. True False 
4. I dread to think about having to have an operation. True False 
5. I am not at all afraid to die. True False 
6.1 am not particularly afraid of getting cancer. True False 
7. The thought of death never bothers me. True False 
8.1 am often distressed by the way time flies so very rapidly. True False 
9. I fear dying a painful death. True False 
10. The subject of life after death troubles me greatly. True False 
11.1 am really scared of having a heart attack. True False 
12.1 often think about how short life really is. True False 
13. I shudder when I hear people talk about a World War III. True False 
14. The sight of a dead body is horrifying to me. True False 
15.1 feel that the future holds nothing for me to fear. True False 
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Appendix K 
Multidimensional Aids Anxiety Questionnaire 
107 
The items listed below refer to feelings and reactions that people may experience about 
the disease AIDS (Acquired Immune Deficiency Syndrome). As such, there are no right 
or wrong answers, only the individual reactions that people have. We are interested in 
how typical these feelings and behaviors are of you. To provide your responses, use the 
following scale to indicate how characteristic the following statements are of you: 
1 = Not at all characteristic of me. 
2 = Slightly characteristic of me. 
3 = Somewhat characteristic of me. 
4 = Moderately characteristic of me. 
5 = Very characteristic of me. 
NOTE: Remember to respond to all items, even if you are not completely sure. 
Also, please be honest in responding to these statements. 
Thinking about AIDS makes me feel anxious. __.© © © © 
I sometimes find it hard to discuss issues dealing with AIDS © - - - __.© ® © © 
I feel tense when I think about the threat of AIDS © - - - __.© ® © © 
I feel quite anxious about the epidemic of AIDS © - - - __.© ® © © 
I feel scared about AIDS when I think about sexual relationships © - - - ___© ® © © 
I'm afraid of getting AIDS © - - - ® © © 
I have trouble talking about AIDS with an intimate partner ___© ® © © 
I feel frustrated when I realize the threat of AIDS © - - - . _ . © ® © © 
The disease AIDS makes me feel nervous and anxious © - - - __.© ® © © 
I feel scared when I think about catching AIDS from a sexual 
partner © - - - - _ - © © © © 
I'm not worried about getting AIDS © - - - ___© © © © 
I would feel shy discussing AIDS with an intimate partner © - - - ___© ® © © 
My heart beats fast with anxiety when I think about AIDS © - - - ___© ® © © 
I feel anxious when I talk about AIDS with people © - - - _._© ® © © 
Because of AIDS. I feel nervous about initiating sexual relations - . . © © © © 
All these discussions of AIDS leaves me feeling a bit alarmed © - - - ___© © © © 
I would not find it hard to discuss AIDS with an intimate partner © - - - ___© © © © 
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AIDS makes me feel jittery about having sex with someone CD © © © © 
I feel uncomfortable when discussing AIDS ® © © © © 
I sometimes worry that one of my past sexual partners may have 
had AIDS © © © © © 
Thinking about catching AIDS leaves me feeling concerned © © ® © © 
I would not hesitate to ask a former sex partner about AIDS-
related concerns © © ® © © 
The issue of AIDS is a very stressful experience for me © © © © © 
I feel nervous when I discuss AIDS with another person © © © © © 
The threat of getting AIDS makes me feel uneasy about sex © © © © © I worry about what I should do about AIDS © © © © © 
Anxiety about AIDS is beginning to affect my personal 
relationships © © © © © 
In general, the media attention on AIDS makes me feel restless © © © © © 
I have feelings of worry when I think about AIDS © © © © © 
Were I to have sexual relations, I would worry about getting 
AIDS © © ® © © 
All this recent media attention about AIDS leaves me feeling on 
edge © © ® © © 
AIDS does not influence my willingness to engage in sexual 
relationships © © ® © © 
When I think about AIDS, I feel tense © ® © © © 
I am more anxious than most people are about the disease AIDS © ® ® © © 
If I were to have sex with someone, I would worry about AIDS © © © © © 
I'm pretty indifferent to the idea of catching AIDS © © © © © 
I would hesitate o involve myself in a sexual relationship 
because of AIDS © © © © © 
When talking about AIDS with someone, I feel jumpy and high-
strung © © ® © © 
I become really frightened when I think about the threat of 
AIDS © © © © © 
The fear of AIDS makes me feel nervous about engaging in sex © © ® © © 
The increased chances of being infected with AIDS leaves me 
feeling troubled © © ® © © 
Because of AIDS, I feel too nervous to start a new sexual 
relationship © © © © © 
The spread of AIDS is causing me to feel quite a bit of stress © © © © © 
I worry that AIDS may directly influence my life © © ® © © 
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I had a better attitude towards sex before the AIDS epidemic © © © © © 
I get pretty upset when I think about the possibility of catching 
AIDS © © © © © 
The discussion of AIDS makes me feel uncomfortable © © © © © 
All this talk about AIDS has left me feeling strained and tense © © © © © 
I'm concerned that I might be carrying the AIDS virus © © © © © I feel nervous when I think that a past sexual partner could have 
given me AIDS © © © © © 
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Appendix L 
HIV risk assessment 
I l l 
Since your last HIV test (if ever), have you... 
1. .. .injected drugs and shared equipment (e.g., needles, syringes, 
cotton, water) with others? Yes No 
2. .. .had unprotected intercourse with someone that you think might 
be infected (e.g., a partner who injected drugs, has been diagnosed 
or treated for a sexually transmitted disease [STD] or hepatitis, has 
had multiple or anonymous sex partners, or has exchanged sex for 
drugs or money)? Yes No 
3. .. .had unprotected vaginal or anal intercourse with more than one sex 
partner? Yes No 
4. .. .been diagnosed or treated for an STD, hepatitis, or tuberculosis? Yes No 
5. .. .had a fever or illness of unknown cause? Yes No 
6. .. .been told you have an infection related to a 'weak immune system'? Yes No 
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Appendix M 
HIV Knowledge Questionnaire 
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Please circle whether the following statements are True or False. 
1. Coughing and sneezing DO NOT spread HIV True False 
2. A person can get HIV by sharing a glass of water with someone who has HIV True False 
3. Pulling out the penis before a man climaxes/cums keeps a woman from 
getting HIV during sex True False 
4. A woman can get HIV if she has anal sex with a man True False 
5. Showering, or washing one's genitals/ private parts, after sex keeps 
a person from getting HIV True False 
6. All pregnant women infected with HIV will have babies born with AIDS True False 
7.People who have been infected with HIV quickly show serious signs of 
being infected True False 
8. There is a vaccine that can stop adults from getting HIV True False 
9. People are likely to get HIV by deep kissing, putting their tongue in 
their partner's mouth, if their partner has HIV True False 
10. A woman cannot get HIV if she has sex during her period True False 
11. There is a female condom that can help decrease a woman's chance 
of getting HIV True False 
12. A natural skin condom works better against HIV than does a latex 
condom True False 
13. A person will NOT get HIV if she or he is taking antibiotics True False 
14. Having sex with more than one partner can increase a person's chance 
of being infected with HIV True False 
15. Taking a test for HIV one week after having sex will tell a person if 
she or he has HIV True False 
16. A person can get HIV by sitting in a hot tub or a swimming pool with 
a person who has HIV True False 
17. A person can get HIV from oral sex True False 
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18. Using Vaseline or baby oil with condoms lowers the chance of getting 
HIV True False 
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Appendix N 
Human Subjects Review Board Approval 
116 
WESTERN KENTUCKY UNIVERSITY 
Human Subjects Review Board 
Office of Sponsored Programs 
301 Potter Hall 
270-745-4652; Fax 270-745-4211 
E-mail: Sean. Rubino@wku.edu 
In future correspondence please refer to HS07-129, February 7, 2007 
Ilze Nix 
c/o Dr. Phil Pegg 
Department of Psychology 
WKU 
Dear Ilze: 
Your revision to your research project, "Personal Medical Questionnaire," was reviewed by the 
HSRB and it has been determined that risks to subjects are: (1) minimized and reasonable; and 
that (2) research procedures are consistent with a sound research design and do not expose the 
subjects to unnecessary risk. Reviewers determined that: (1) benefits to subjects are considered 
along with the importance of the topic and that outcomes are reasonable; (2) selection of subjects 
is equitable; and (3) the purposes of the research and the research setting is amenable to subjects' 
welfare and producing desired outcomes; that indications of coercion or prejudice are absent, and 
that participation 
is clearly voluntary. 
In addition, the IRB found that you need to orient participants as follows: (1) signed informed 
consent is required; (2) Provision is made for collecting, using and storing data in a manner that 
protects the safety and privacy of the subjects and the confidentiality of the data. (3) Appropriate 
safeguards are included to protect the rights and welfare of the subjects. 
This project is therefore approved at the Expedited Review Level until May 31, 2007. 
Please note that the institution is not responsible for any actions regarding this protocol before 
approval. If you expand the project at a later date to use other instruments please re-apply. Copies 
of your request for human subjects review, your application, and this approval, are maintained in 
the Office of Sponsored Programs at the above address. Please report any changes to this 
approved protocol to this office. Also, please use the stamped Informed Consent documents that 
are included with this letter. A Continuing Review protocol will be sent to you in the future to 
determine the status of the project. 
Sincerely, 
Sean Rubino, M.P.A. 
Compliance Manager 
Office of Sponsored Programs 
Western Kentucky University 
cc: HS file number Nix HS07-129 
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Appendix O 
Informed Consent 
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You are being asked to participate in a study that will evaluate your attitudes and 
behavior patterns with relation to medical behavior. Please read the following material 
thoroughly. It describes the purpose of the study in brief, the procedure to be used, risks 
and benefits of your participation, and what will be done to the information that is being 
collected from you. This study is being conducted through Western Kentucky 
University. The University requires that you give your signed agreement to participate in 
this project. 
The investigator will explain to you the purpose of the project, the procedures to 
be used, and the potential benefits and possible risks of participation. You may ask her or 
him any questions you have to help you understand the project. A basic explanation of 
the project is provided below. Please read this explanation and discuss with the researcher 
any questions you may have. 
If you then decide to participate in the project, please sign on the last page of this 
form in the presence of the person who explained the project to you. By signing this 
form, you are indicating that you are aware of the risks and benefits of this project. 
This project is completely voluntary. You do not have to participate under any 
circumstance. 
1. PROJECT TITLE 
Personal Medical Behavior Questionnaire 
2. PRINCIPAL INVESTIGATOR 
Ilze Nix, graduate student, (ilze.nix@wku.edu) 
Dr. Phil Pegg, faculty supervisor, (phil.pegg@wku.edu) 
Western Kentucky University, Department of Psychology, (270) 745-4417 
3. NATURE AND PURPOSE OF THE PROJECT 
The purpose of this study is to evaluate personal health practices and attitudes. 
4. EXPLANATION OF PROCEDURES 
You will be asked to complete a questionnaire regarding demographic 
information (i.e. questions about yourself) as well various questionnaires designed to 
assess your personal health practices and behaviors. This session will take about 60 
minutes. 
5. DISCOMFORT AND RISKS 
We are looking for your honest answers to these surveys. There is minimal risk 
that the information on the questionnaires may cause any psychological distress. If this 
occurs, please inform your researcher. 
6. BENEFITS 
As a participant in the study, you will be contributing to science and helping 
researchers gain more knowledge that will foster a better understanding about the various 
attitudes and behavior patterns people have with relation to medical behavior. If you are a 
student of Western Kentucky University an additional benefit to you is that extra credit 
for participation may be granted or the involvement in this study might fulfill the research 
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requirements of Introduction to Psychology, all at the discretion of your class professors. 
No other inducements will be offered. 
7. CONFIDENTIALITY 
You will be asked to choose your own unique pseudonym that you will need to 
indicate on your questionnaire packet or at the conclusion of the Internet survey. This 
pseudonym will be the only 'identifying' information directly provided as part of the 
packet. You will be required to provide the information needed (i.e. your name and WKU 
ID) and your chosen pseudonym on along with a signed copy of the Informed Consent 
page, regardless of whether you complete the study in paper-pencil format or online. The 
informed consent page and pseudonym information will be kept separate from the 
collected response and will only be used to assign extra credit. Furthermore, each 
participant will be assigned a unique identification number by the researchers. This 
identification number (unique to each of the participants) will be used to make sure that 
no duplicate data will be entered in the database. 
Your identity and the identity of all participants will never be revealed in any 
published or oral presentation of the results of this project. All data from this project will 
be kept confidential to the extent of the law. All data that is published or presented will 
be done in a way that does not reveal the identity of a participant. 
8. REFUSAL/WITHDRAWAL 
Refusal to participate in this study will have no effect on any future services 
that you may be entitled to from the University. Anyone who agrees to participate in this 
study is free to withdraw from the study at any time with no penalty. 
You understand also that it is not possible to identify all potential risks in an 
experimental procedure, and you believe that reasonable safeguards have been taken to 
minimize both the known and potential but unknown risks. 
Pseudonym: 
Signature of Participant Date 
Witness Date 
THE DATED APPROVAL ON THIS CONSENT FORM INDICATES THAT 
PROJECT HAS BEEN REVIEWED AND APPROVED BY THE WESTERN KENTUCKY 
UNIVERSITY HUMAN SUBJECTS REVIEW BOARD 
Dr. Phillip E. Meyers, Human Protections Administrator 
TELEPHONE: (270) 745-4652 
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Debriefing Form 
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We would like to thank you for your participation in this research. Your contribution will 
add to the knowledge base concerning the HIV testing behavior. A better understanding 
of this could lead to an improvement in the services provided to you and other 
participants, and might lead to better advice and support offered to individuals when they 
participate in HIV testing. Furthermore, the community at large can benefit as a clearer 
understanding of HIV testing behavior may lead to an increase in the number of 
individuals who choose to become aware of their HIV status by taking a HIV test. 
If you would like to determine your own HIV status, following is a list of resources 
available to you. 
1. WKU Health Services 
o 1906 College Heights Blvd. #8400; Bowling Green, Kentucky; 42101 
o Phone:(270)745-5641 
o Operating Hours: Monday - Thursday 8am-4:30pm / Friday 10am-
4:30pm 
o Email: wkuhealthservices@wku.edu 
2. Barren River District Health Department 
o 1109 State St; PO Box 1157; Bowling Green, KY; 42102 
o Phone: (270) 781-8039 
3. Center for Disease Control 
o Phone: CDC-INFO 24 Hours/Day at I-8OO-CDC-INFO (232-4636), 1-
888-232-6348 (TTY), in English, en Espanol. 
o Website: http://www.hivtcst.org/ 
If you would like more information about HIV/ AIDS, following is a list of 
credible websites available to you. 
1. http://www.cdc.gov/hiv/ 
2. http://chfs.ky.gov/dph/epi/1iivaids.htm 
3. http://www.aids.gov/ 
4. http://www.aidsinfo,nih.gov/ 
In the event that the information on the questionnaires may have caused you any 
psychological distress please inform the researcher. Additionally, services are available 
through Western Kentucky University that you can utilize in such an event. Please 
contact the Counseling and Testing Center at 409 Potter Hall, 1906; College Heights 
Blvd. #1102; Bowling Green KY; 42101. 
Phone: (270) 745-3159 
Email: counseling@wku.edu 
